[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 172
1. Salaverria I, Zettl A, Beà S, Hartmann EM, Dave SS, Wright GW, Boerma EJ, Kluin PM, Ott G, Chan WC, Weisenburger DD, Lopez-Guillermo A, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Jaffe ES, Staudt LM, Müller-Hermelink HK, Campo E, Rosenwald A, Leukemia and Lymphoma Molecular Profiling Project (LLMPP): Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. Haematologica; 2008 Sep;93(9):1327-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma.
  • BACKGROUND: Burkitt's lymphoma is an aggressive B-cell lymphoma characterized by typical morphological, immunophenotypic and molecular features.
  • Gene expression profiling provided a molecular signature of Burkitt's lymphoma, but also demonstrated that a subset of aggressive B-cell lymphomas not fulfilling the current World Health Organization criteria for the diagnosis of Burkitt's lymphoma nonetheless show a molecular signature of Burkitt's lymphoma ('discrepant Burkitt's lymphoma').
  • Given the different treatment of Burkitt's lymphoma and diffuse large B-cell lymphomas we investigated molecular differences within gene expression-defined Burkitt's lymphoma.
  • DESIGN AND METHODS: We studied tumors from 51 Burkitt's lymphoma patients, comprising 26 with classic Burkitt's lymphoma, 17 with atypical Burkitt's lymphoma and 8 with 'discrepant Burkitt's lymphoma', by comparative genomic hybridization and gene expression profiling.
  • RESULTS: Classic and atypical Burkitt's lymphoma (excluding 'discrepant Burkitt's lymphoma'), in adult and pediatric cases do not differ in underlying genomic imbalances or gene expression suggesting that these subgroups are molecularly homogeneous.
  • 'Discrepant Burkitt's lymphoma', however, differ dramatically in the absolute number of alterations from classic/atypical Burkitt's lymphoma and from diffuse large B-cell lymphoma.
  • Moreover, this category includes lymphomas that carry both the t(14;18) and t(8;14) translocations and are clinically characterized by presentation in adult patients and an aggressive course.
  • CONCLUSIONS: Pediatric and adult Burkitt's lymphoma are molecularly homogeneous, whereas 'discrepant Burkitt's lymphoma' differ in underlying genetic and clinical features from typical/atypical Burkitt's lymphoma.
  • 'Discrepant Burkitt's lymphoma' may therefore form a distinct genetic subgroup of aggressive B-cell lymphomas, which show poor response to multi-agent chemotherapy.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosomes, Human / genetics. Comparative Genomic Hybridization. Gene Expression Regulation, Neoplastic / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18698080.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / UO1-CA84967
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


2. Lamvik J, Waage A, Wahl SG, Naess I, Paulsen PQ, Hammerstrøm J: Adult acute lymphoblastic leukemia, Burkitt's lymphoma and lymphoblastic lymphoma in middle Norway 1985-2004. Haematologica; 2006 Oct;91(10):1428-9
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult acute lymphoblastic leukemia, Burkitt's lymphoma and lymphoblastic lymphoma in middle Norway 1985-2004.
  • We report a population-based investigation on adult acute precursor B lymphoblastic leukemia, Burkitt's lymphoma and T lymphoblastic lymphoma in a defined geographic area.
  • [MeSH-major] Burkitt Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Hematopoietic Stem Cells / pathology. Humans. Incidence. Male. Middle Aged. Norway / epidemiology


3. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project: Molecular diagnosis of Burkitt's lymphoma. N Engl J Med; 2006 Jun 8;354(23):2431-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnosis of Burkitt's lymphoma.
  • BACKGROUND: The distinction between Burkitt's lymphoma and diffuse large-B-cell lymphoma is crucial because these two types of lymphoma require different treatments.
  • We examined whether gene-expression profiling could reliably distinguish Burkitt's lymphoma from diffuse large-B-cell lymphoma.
  • RESULTS: A classifier based on gene expression correctly identified all 25 pathologically verified cases of classic Burkitt's lymphoma.
  • Burkitt's lymphoma was readily distinguished from diffuse large-B-cell lymphoma by the high level of expression of c-myc target genes, the expression of a subgroup of germinal-center B-cell genes, and the low level of expression of major-histocompatibility-complex class I genes and nuclear factor-kappaB target genes.
  • Eight specimens with a pathological diagnosis of diffuse large-B-cell lymphoma had the typical gene-expression profile of Burkitt's lymphoma, suggesting they represent cases of Burkitt's lymphoma that are difficult to diagnose by current methods.
  • Among 28 of the patients with a molecular diagnosis of Burkitt's lymphoma, the overall survival was superior among those who had received intensive chemotherapy regimens instead of lower-dose regimens.
  • CONCLUSIONS: Gene-expression profiling is an accurate, quantitative method for distinguishing Burkitt's lymphoma from diffuse large-B-cell lymphoma.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / genetics. Gene Expression. Gene Expression Profiling. Lymphoma, B-Cell / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bayes Theorem. Child. Child, Preschool. Diagnosis, Differential. Female. Follow-Up Studies. Genes, MHC Class I. Genes, myc. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. NF-kappa B / genetics. Oligonucleotide Array Sequence Analysis. Survival Analysis. Transcription, Genetic. Translocation, Genetic


Advertisement
4. Martos-Díaz P, Bances-del-Castillo R, Vidal-Laso R, Mancha-de-la-Plata M, Cho-Lee GY, Naval-Gías L: Bilateral mental nerve neuropathy as the sole presenting symptom of Burkitt's Lymphoma. Med Oral Patol Oral Cir Bucal; 2009 Aug;14(8):e408-10
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral mental nerve neuropathy as the sole presenting symptom of Burkitt's Lymphoma.
  • Among these pathologies, we have focused on intrabone growing tumours such as Burkitt's Lymphoma.
  • Burkitt's Lymphoma is a malignant tumour of B-Cell lymphocyte origin, classified as a Non-Hodgkin's Lymphoma.
  • It is characterized by very fast growing, undifferentiated lymphocytes and bone marrow infiltration.
  • A high incidence of Burkitt's Lymphoma has been reported in African children.
  • This report describes the case of a 29 year-old Spanish man diagnosed with Burkitt's Lymphoma, in which his first and only symptom was bilateral anaesthesia of the lower lip.
  • [MeSH-major] Burkitt Lymphoma / complications. Cranial Nerve Diseases / etiology. Mandibular Neoplasms / complications. Mandibular Nerve
  • [MeSH-minor] Adult. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415057.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


5. Ogawa T, Mizutani M, Yabana T, Miyahara S, Murabayashi K: A Case of Burkitt's Lymphoma Involving Both Breasts. Breast Cancer; 2005;12(3):234-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Case of Burkitt's Lymphoma Involving Both Breasts.
  • Primary malignant lymphoma of the breast is rare, and Burkitt's lymphoma is especially rare.
  • We report the case of a 44-year-old woman in whom Burkitt's lymphoma involving both breasts was diagnosed.
  • The patient was referred to our hospital because of a diffuse, firm swelling, like a bulky ball, in both breasts.
  • Fine-needle aspiration cytology (FNAC) of both breast masses revealed malignant lymphoma(ML), and diffuse large B-cell lymphoma was diagnosed based on the results of immunohistochemical studies of a core needle biopsy specimen.
  • We then resected the mass in the left breast, and when examination of the surgical specimen revealed relapse of ML and t (8;11) (q24;q32) translocation, Burkitt's lymphoma was diagnosed.
  • High-dose chemotherapy followed by peripheral-blood stem cell transplantation was performed, but the patient died 10 months after her initial presentation at our hospital.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / diagnosis. Burkitt Lymphoma / diagnosis. Diagnostic Errors
  • [MeSH-minor] Adult. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Fatal Outcome. Female. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Peripheral Blood Stem Cell Transplantation. Prednisone / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110296.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHASE protocol; CHOP protocol
  •  go-up   go-down


6. Lee SH, Kim HJ, Mun JS, Oh HC, Lee HW, Choi CH, Kim JW, Do JH, Kim JG, Chang SK, Kim MK: A case of primary hepatic Burkitt's lymphoma. Korean J Gastroenterol; 2008 Apr;51(4):259-64
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary hepatic Burkitt's lymphoma.
  • Burkitt's lymphoma is a rare disease that belongs to the aggressive non-Hodgkin's lymphoma.
  • Herein, we report a case of primary hepatic Burkitt's lymphoma.
  • Abdominal-Pelvis CT scan and abdominal MRI finding were compatible with malignant lymphoma.
  • Liver biopsy examination confirmed Burkitt's lymphoma.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Cytarabine / therapeutic use. Diagnosis, Differential. Humans. Male. Methotrexate / therapeutic use. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18516006.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


7. Baumgaertner I, Copie-Bergman C, Levy M, Haioun C, Charachon A, Baia M, Sobhani I, Delchier JC: Complete remission of gastric Burkitt's lymphoma after eradication of Helicobacter pylori. World J Gastroenterol; 2009 Dec 7;15(45):5746-50
Hazardous Substances Data Bank. PANTOPRAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of gastric Burkitt's lymphoma after eradication of Helicobacter pylori.
  • Burkitt's lymphoma is a highly aggressive non-Hodgkin lymphoma, often presenting in extra-nodal sites.
  • We report the case of a 39-year old woman who presented with a prominent ulcerated lesion of the antrum corresponding histologically to a Burkitt's lymphoma associated with Helicobacter pylori (H pylori) infection.
  • This is the first report of a gastric Burkitt's lymphoma responding to H pylori eradication.
  • These findings raise the question of the potential role of H pylori in the pathogenesis of some gastric Burkitt's lymphomas, and show the importance of searching for and eradicating the bacteria in combination with conventional chemotherapy regimens.
  • [MeSH-major] Burkitt Lymphoma. Helicobacter Infections / drug therapy. Helicobacter pylori. Stomach Neoplasms
  • [MeSH-minor] 2-Pyridinylmethylsulfinylbenzimidazoles / therapeutic use. Adult. Anti-Ulcer Agents / therapeutic use. Female. Gastric Mucosa / microbiology. Gastric Mucosa / pathology. Humans. Remission Induction. Treatment Outcome


8. Bociek RG: Adult Burkitt's lymphoma. Clin Lymphoma; 2005 Jun;6(1):11-20
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult Burkitt's lymphoma.
  • Burkitt's lymphoma is a mature B-cell lymphoma that is characterized by a rapid proliferative rate and propensity for extranodal sites of involvement such as the gastrointestinal tract and central nervous system.
  • This subtype of non-Hodgkin's lymphoma is associated with unique cytogenetic translocations involving the c-MYC oncogene on chromosome 8, which appears to be involved in the pathogenesis of this disease.
  • Although current literature is limited by a lack of randomized trials, Burkitt's lymphoma appears to be curable in a high proportion of cases if treated with aggressive multiagent chemotherapy regimens.
  • The use of autologous stem cell transplantation appears to benefit patients who have had chemotherapy-sensitive relapses.
  • The role of allogeneic stem cell transplantation for this disease remains uncertain.
  • Patients with HIV-associated Burkitt's lymphoma appear to have a better prognosis today, which is likely a result of more effective antiretroviral therapy and the ability to treat selected patients with more aggressive chemotherapeutic regimens than before.
  • This article will review the epidemiologic, biologic, diagnostic, and therapeutic aspects of Burkitt's lymphoma in adults.
  • [MeSH-major] Burkitt Lymphoma
  • [MeSH-minor] Adult. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15989701.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


9. Malani AK, Gupta C, Weigand RT, Gupta V, Rangineni G: Spinal Burkitt's lymphoma in adults. Clin Lymphoma Myeloma; 2006 Jan;6(4):333-6
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal Burkitt's lymphoma in adults.
  • Adult Burkitt's lymphoma is an uncommon disease.
  • Few cases of spinal involvement in adults with sporadic Burkitt's lymphoma are reported in the literature.
  • Histologic examination revealed a primary Burkitt's lymphoma of the spinal cord.
  • We also present a review of the literature for the etiology and clinical features of other spinal lymphomas and Burkitt's lymphoma involving the spine in adults.
  • [MeSH-major] Burkitt Lymphoma / pathology. Epidural Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16507212.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Gutiérrez-García L, Medina Ramos N, García Rodríguez R, Barber MA, Arias MD, García JA: Bilateral ovarian Burkitt's lymphoma. Eur J Gynaecol Oncol; 2009;30(2):231-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral ovarian Burkitt's lymphoma.
  • Primary ovarian lymphoma is a rare entity.
  • Histology confirmed Epstein-Barr virus-positive bilateral Burkitt's lymphoma.
  • Endemic Burkitt's lymphoma has a predilection for the female genital tract, manifesting itself clinically as a pelvic mass and less frequently as a menstrual disorder.
  • [MeSH-major] Burkitt Lymphoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Herpesvirus 4, Human / isolation & purification. Humans

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480266.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Magloire LK, Pettker CM, Buhimschi CS, Funai EF: Burkitt's lymphoma of the ovary in pregnancy. Obstet Gynecol; 2006 Sep;108(3 Pt 2):743-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma of the ovary in pregnancy.
  • BACKGROUND: Burkitt's lymphoma is a rapidly growing and, if untreated, rapidly fatal tumor derived from B-lymphocytes.
  • The occurrence of Burkitt's lymphoma during pregnancy is rare.
  • CASE: A patient with Burkitt's lymphoma presented at 12 weeks of gestation with abdominal and tooth pain.
  • The pathology examination confirmed lymphoma in the left ovary and in the tissue surrounding the extracted tooth.
  • CONCLUSION: The finding of an adnexal mass in conjunction with head and neck symptoms led to consideration of Burkitt's lymphoma.
  • Prompt treatment with multiagent chemotherapy should be considered for pregnant patients with Burkitt's lymphoma.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Ovarian Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fallopian Tubes / surgery. Female. Gestational Age. Humans. Infant, Low Birth Weight. Infant, Newborn. Mouth Neoplasms / diagnosis. Mouth Neoplasms / drug therapy. Mouth Neoplasms / surgery. Ovariectomy. Pain. Pregnancy. Pregnancy Outcome. Tooth. Ultrasonography


12. Paissan A, Wachs A, Arias M, Abeldaño A, Frider B: [Obstructive jaundice associated Burkitt's lymphoma mimicking pancreatic carcinoma]. Acta Gastroenterol Latinoam; 2007 Dec;37(4):246-9
Hazardous Substances Data Bank. HYDROCORTISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Obstructive jaundice associated Burkitt's lymphoma mimicking pancreatic carcinoma].
  • [Transliterated title] Ictericia obstructiva asociada a linfoma de Burkitt en un adulto inmunocompetente.
  • However, in advanced stages of Non-Hodgkin's lymphomas (LNH) the secondary invasion of the pancreas is observed more frequently.
  • The aim is to present a case of an obstructive jaundice as an expression of Burkitt's lymphoma probably due to a diffuse pancreatic infiltration in an adult without immunodeficiency with a rapid response of cholestasis to low dose of hydrocortisone.
  • There are isolated reports of Burkitt's lymphoma cases with associated obstructive jaundice due to pancreatic infiltration or by compression by lymph nodes of the bile ducts, many of them are pediatric cases or immunodepressed HIV patients.
  • We think the interest in this case is the quick response to low doses of corticoids, which avoided the necessity of surgical procedure for the diagnosis of the biliary tree obstruction, allowing a quick implementation of the specific chemotherapeutic treatment of the lymphoma without any surgical or endoscopic procedures to heal the jaundice.
  • [MeSH-major] Burkitt Lymphoma / complications. Jaundice, Obstructive / etiology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Anti-Inflammatory Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Fatal Outcome. Humans. Hydrocortisone / therapeutic use. Male

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18254263.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


13. Karantanis D, Durski JM, Lowe VJ, Nathan MA, Mullan BP, Georgiou E, Johnston PB, Wiseman GA: 18F-FDG PET and PET/CT in Burkitt's lymphoma. Eur J Radiol; 2010 Jul;75(1):e68-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET and PET/CT in Burkitt's lymphoma.
  • OBJECTIVE: To explore the value of (18)F fluorodeoxy-glucose (FDG) positron emission tomography (PET) in Burkitt's lymphoma.
  • METHODS: All Burkitt's lymphoma patients referred for FDG PET or FDG PET/computed tomography (CT) exams at our institution from June 2003 to June 2006 were included.
  • CONCLUSIONS: FDG PET-PET/CT is sensitive for the detection of viable disease in Burkitt's lymphoma.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Subtraction Technique. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity. Young Adult

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19716248.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


14. Liang CW, Li HY, Chang KP, Chen CK, Chen YL: HIV infection initially presenting as sinonasal Burkitt's lymphoma. Am J Otolaryngol; 2006 Nov-Dec;27(6):433-5
MedlinePlus Health Information. consumer health - Sinusitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV infection initially presenting as sinonasal Burkitt's lymphoma.
  • Burkitt's lymphoma is a common comorbidity of infection with the human immunodeficiency virus, but rarely the initial clinical manifestation of undiagnosed AIDS, especially for the otolaryngologist.
  • We report the case of a patient with recalcitrant rhinosinusitis subsequently diagnosed with sinonasal Burkitt's lymphoma and HIV.
  • [MeSH-major] Burkitt Lymphoma / radiography. HIV Infections / radiography. Sinusitis / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Paranasal Sinuses / radiography. Rhinitis / diagnosis. Rhinitis / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084232.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Kyoung Jung H, Kim EK, Yun M, Jung Kim M, Young Kwak J: Bilateral breasts involvement in Burkitt's lymphoma detected only by FDG-PET. Clin Imaging; 2006 Jan-Feb;30(1):57-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral breasts involvement in Burkitt's lymphoma detected only by FDG-PET.
  • Burkitt's lymphoma can occur from elsewhere in the body, but involvement of the breasts is very rare.
  • However, we experienced the involvement of bilateral whole breasts in a patient with underlying Burkitt's lymphoma, which showed negative mammographic and ultrasonographic findings, but bilateral hot uptakes of the breast in FDG-PET scan.
  • [MeSH-major] Breast Neoplasms / diagnosis. Burkitt Lymphoma / diagnosis. Positron-Emission Tomography
  • [MeSH-minor] Adult. Fatal Outcome. Female. Fluorodeoxyglucose F18. Humans. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16377487.001).
  • [ISSN] 0899-7071
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


16. Caces DD, Halaas J, Hamlin P, Noy A, Kewalramani T, Portlock CS, Zelenetz AD, O'Connor OA, Gerecitano JF: Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19554

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma.
  • : e19554 Background: Multiple reports corroborate a role for irinotecan in the treatment of lymphoma.
  • This study describes the Memorial Sloan Kettering experience with single-agent irinotecan in the management of heavily pretreated and highly refractory cases of lymphoma.
  • METHODS: Adult patients with histologically diagnosed relapsed or refractory lymphoma treated with irinotecan between 1/2001 and 8/2008 were identified.
  • Treatment responses were evaluated based on the Revised Response Criteria for Malignant Lymphoma.
  • 4 patients had Hodgkin Lymphoma (HL) and 26 had Non-Hodgkin lymphoma (NHL): 17 DLBCL, 6 transformed follicular lymphoma, 1 mantle cell lymphoma, 1 T-cell lymphoma and 1 Burkitt's. 25 patients were evaluable for response.
  • CONCLUSIONS: Irinotecan has utility even in multiply treated and highly refractory cases of lymphoma.
  • Strategies that limit adverse reactions may enhance the agent's effectiveness in refractory lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961088.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Lin H, Sun XF, Zhen ZJ, Xia Y, Xiang XJ, Ling JY, Liu DG, Xia ZJ, Huang HQ, Luo WB, Zheng L, Lin TY, Guan ZZ: [Clinical analysis of 69 cases of Burkitt's lymphoma]. Ai Zheng; 2008 Apr;27(4):425-8
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 69 cases of Burkitt's lymphoma].
  • BACKGROUND & OBJECTIVE: Burkitt's lymphoma is a kind of highly aggressive B-cell lymphoma.
  • There is no large-scale report concerning Burkitt's lymphoma in China yet.
  • This study was to summarize the characteristics of Burkitt's lymphoma in China.
  • METHODS: Clinical data of 69 Burkitt's lymphoma patients, treated from May 1985 to May 2007 in Cancer Center of Sun Yat-sen University, were analyzed.
  • CONCLUSION: The clinical characteristics of these 69 Burkitt's lymphoma patients are much similar to those from sporadic areas, but the median age is lower, and the most common involved sites are cervical lymph nodes, abdomen and faciomaxillary-oropharynx.
  • [MeSH-major] Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Herpesvirus 4, Human / isolation & purification. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18423131.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


18. Chen ZY, Wu B, Yin JL: Intensive chemotherapy failure in Burkitt's lymphoma with cavernous sinus involvement. Med Oncol; 2010 Jun;27(2):327-31
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy failure in Burkitt's lymphoma with cavernous sinus involvement.
  • Burkitt's lymphoma is an aggressive B-cell lymphoma with rapid proliferative index, which makes it disseminate easily to distal sites, especially to bone marrow and the central nerve system.
  • We report here a 22-year-old woman with Burkitt's lymphoma involving multiple organs, including kidneys, breasts, left ovary, and bone marrow at the time of diagnosis.
  • Further study should provide well-designed therapeutic strategies to Burkitt's patients with cavernous sinus involvement.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / drug therapy. Cavernous Sinus / pathology
  • [MeSH-minor] Fatal Outcome. Female. Humans. Treatment Failure. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19365738.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Cascarini L, Brown AE: Burkitt's lymphoma: an unusual cause of lip numbness. Dent Update; 2005 Mar;32(2):97-8, 100
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma: an unusual cause of lip numbness.
  • Dental infection secondary to caries was initially diagnosed but biopsy revealed this to be a Burkitt's lymphoma.
  • [MeSH-major] Burkitt Lymphoma / complications. Hypesthesia / etiology. Lip Diseases / etiology. Mandibular Neoplasms / complications
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Remission Induction. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dent Update. 2005 Jul-Aug;32(6):363; author reply 363 [16117360.001]
  • (PMID = 15819153.001).
  • [ISSN] 0305-5000
  • [Journal-full-title] Dental update
  • [ISO-abbreviation] Dent Update
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol
  •  go-up   go-down


20. Lam MS: Treatment of Burkitt's lymphoma during pregnancy. Ann Pharmacother; 2006 Nov;40(11):2048-52
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Burkitt's lymphoma during pregnancy.
  • OBJECTIVE: To report a case of both successful maternal treatment outcome and normal fetal outcome in a patient who was diagnosed with Burkitt's lymphoma (BL) and aggressively treated with 6 different chemotherapy agents during the second and third trimesters of pregnancy.
  • [MeSH-major] Burkitt Lymphoma / drug therapy. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Ifosfamide / therapeutic use. Infant, Newborn. Male. Methotrexate / therapeutic use. Pregnancy. Registries. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17062832.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol; IVAC protocol
  •  go-up   go-down


21. Cordeiro A, Machado AI, Borges A, Alves MJ, Frade MJ: Burkitt's lymphoma related to Epstein-Barr virus infection during pregnancy. Arch Gynecol Obstet; 2009 Aug;280(2):297-300
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma related to Epstein-Barr virus infection during pregnancy.
  • SETTING: Burkitt's lymphoma is a rare form of cancer and is an extremely rare diagnosis during pregnancy.
  • This form of lymphoma is a very fast growing B cell neoplasm and chemotherapy is the treatment of choice for the disease in all its stages.
  • CASE REPORT: The authors describe the case of a Caucasian 40-year-old nulliparous woman, with previous known Epstein-Barr virus infection, that presents at 28 weeks gestation with supraclavicular adenopathy and multiple bilateral breast nodules, in which biopsy showed non-Hodgkin lymphoma, Burkitt's type.
  • DISCUSSION: There are few described cases of Burkitt's lymphoma during pregnancy and in general the outcomes have been poor.
  • [MeSH-major] Burkitt Lymphoma / virology. Epstein-Barr Virus Infections / complications. Pregnancy Complications, Neoplastic / virology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Female. Humans. Pregnancy. Pregnancy Complications, Infectious

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19107501.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


22. Bariakh EA, Kravchenko SK, Kremenetskaia AM, Zvonkov EE, Obukhova TN, Magomedova AU, Vorob'ev AI: [Clinical and epidemiological features of Burkitt's lymphoma]. Ter Arkh; 2009;81(7):47-53
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and epidemiological features of Burkitt's lymphoma].
  • AIM: To characterize clinical and epidemiological features of adult Berkitt's lymphoma (BL).
  • Murphy) was diagnosed in 5 patients, stage II--in 9, stage III--in 25, IV--in 14 patients, B-cell acute lymphoblastic leukemia (ALL) (L3)--in 19 patients.
  • Fifty two (72%) patients had abdominal, retroperitoneal and/or small pelvis tumors.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Female. Humans. L-Lactate Dehydrogenase / metabolism. Male. Middle Aged. Neoplasm Staging. Sex Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19708573.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


23. Levy J, Kratz A, Lifshitz T: Burkitt's lymphoma presenting as oculomotor palsy in an hiv-positive patient. Eur J Ophthalmol; 2006 Jan-Feb;16(1):186-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma presenting as oculomotor palsy in an hiv-positive patient.
  • PURPOSE: To report a case of Burkitt's lymphoma (BL) in an HIV-positive patient presenting as complete third nerve palsy.
  • RESULTS: Liver biopsy was consistent with Burkitt's lymphoma.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. HIV Seropositivity / diagnosis. Oculomotor Nerve Diseases / diagnosis. Ophthalmoplegia / diagnosis
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / therapeutic use. CD4 Lymphocyte Count. Cytarabine / therapeutic use. Drug Therapy, Combination. Humans. Infusions, Intravenous. Injections, Spinal. Male. Methotrexate / therapeutic use. Tomography, X-Ray Computed. Viral Load


24. Kagu MB, Ahmed SG, Bukar AA: Pre-treatment tumour lysis syndrome and acute renal failure in adult Nigerians with Burkitt's lymphoma: report of three cases and literature review. Afr J Med Med Sci; 2005 Dec;34(4):399-402
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-treatment tumour lysis syndrome and acute renal failure in adult Nigerians with Burkitt's lymphoma: report of three cases and literature review.
  • The overall incidence and frequency is unknown and to the best of our knowledge none has been published in Nigeria involving adult females with advanced stage Burkitt's lymphoma (ASBL).
  • This paper stresses the importance of aggressive supportive management and slow introduction of cytotoxic chemotherapy in patients with a stage C and/or stage D Burkitt's lymphoma presenting with pre-TTLS.
  • [MeSH-major] Burkitt Lymphoma / complications. Renal Insufficiency / etiology. Tumor Lysis Syndrome / etiology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Fatal Outcome. Female. Humans. Nigeria. Risk Assessment. Risk Factors. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16752673.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


25. Adeoye AO, Durosinmi MA, Adeodu OO, Kagu MB, Olateju SO, Olowu WA, Salawu IL, Kazeem OD: Ocular manifestations of Burkitt's lymphoma: experience in Ile-Ife south western Nigeria. West Afr J Med; 2007 Jan-Mar;26(1):48-52
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular manifestations of Burkitt's lymphoma: experience in Ile-Ife south western Nigeria.
  • BACKGROUND: Burkitt's lymphoma is the most common childhood tumour in subSaharan Africa that typically affects the jaws and abdomen.
  • OBJECTIVE: This was to evaluate the role of Burkitt's lymphoma (BL) as a cause of blindness in Nigerian children.
  • CONCLUSION: Burkitt's lymphoma is an important cause of childhood blindness in Nigeria and the orbital disease ismainly extra ocular.
  • [MeSH-major] Burkitt Lymphoma / complications. Exophthalmos / etiology
  • [MeSH-minor] Adolescent. Adult. Blindness / etiology. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Eye Neoplasms / etiology. Female. Geography. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Nigeria / epidemiology. Retrospective Studies. Risk Factors. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17595992.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


26. Okebe JU, Lasserson TJ, Meremikwu MM, Richards S: Therapeutic interventions for Burkitt's lymphoma in children. Cochrane Database Syst Rev; 2006;(4):CD005198
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic interventions for Burkitt's lymphoma in children.
  • BACKGROUND: Burkitt's lymphoma (BL) is a small non-cleaved cell lymphoma which commonly presents as jaw swellings.
  • AUTHORS' CONCLUSIONS: This review does not currently provide any strong evidence on the relative effectiveness of interventions to treat Burkitt's lymphoma.
  • The studies that have been conducted to date are small, underpowered and prone to both systematic and random error.
  • [MeSH-major] Burkitt Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Humans. Randomized Controlled Trials as Topic. Remission Induction

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cochrane Database Syst Rev. 2011;(7):CD005198 [21735399.001]
  • (PMID = 17054245.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 54
  •  go-up   go-down


27. Freudenberg S, Palma P, Grobholz R, Ngendahayo L, Post S: HIV-related and Epstein-Barr virus-associated anal Burkitt's lymphoma: report of a case. Dis Colon Rectum; 2005 Aug;48(8):1656-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-related and Epstein-Barr virus-associated anal Burkitt's lymphoma: report of a case.
  • PURPOSE: This article describes and discusses primary Burkitt's lymphoma of the anus which is an extremely rare site of origin.
  • Histopathology and immunohistology provided evidence of an Epstein-Barr virus-associated Burkitt's lymphoma.
  • CONCLUSIONS: Because of the AIDS epidemic and the increase of anal malignant pathologies, anal Burkitt's lymphoma may appear more frequently.
  • Adequate treatment is available for only a small percentage of patients.
  • [MeSH-major] Anus Neoplasms / diagnosis. Burkitt Lymphoma / diagnosis. Lymphoma, AIDS-Related / diagnosis
  • [MeSH-minor] Adult. Colostomy. Fatal Outcome. HIV Seropositivity / diagnosis. Herpesvirus 4, Human / isolation & purification. Humans. Male. Rectum / surgery

  • Genetic Alliance. consumer health - HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16034658.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Huang YH, Wu QL, Zong YS, Feng YF, Liang JZ, Hou JH, Shao Q, Fu J: Clinicopathologic features and Epstein-Barr virus infection status of Burkitt's lymphoma in Guangzhou district. Ai Zheng; 2009 Aug;28(8):805-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features and Epstein-Barr virus infection status of Burkitt's lymphoma in Guangzhou district.
  • BACKGROUND AND OBJECTIVE: Sporadic Burkitt's lymphoma (sBL) is uncommon and its relation to Epstein-Barr virus (EBV) is unknown in China.
  • A panel of immunohistochemical staining was performed and EBV-encoded small RNAs (EBERs) in situ hybridization was applied to identify EBV infection.
  • RESULTS: From January 2000 to October 2007, 21 cases(0.87%) of sBL were confirmed among 2416 cases of non-Hodgkin's lymphoma(NHL) in Sun Yat-sen University Cancer Center.
  • [MeSH-major] Burkitt Lymphoma / pathology. Burkitt Lymphoma / virology. Epstein-Barr Virus Infections / pathology. Epstein-Barr Virus Infections / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. China. DNA-Binding Proteins / metabolism. Epstein-Barr Virus Nuclear Antigens / metabolism. Female. Follow-Up Studies. Herpesvirus 4, Human / isolation & purification. Humans. Interferon Regulatory Factors / metabolism. L-Lactate Dehydrogenase / metabolism. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Neprilysin / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. RNA, Viral / metabolism. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19664325.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / EBV-encoded nuclear antigen 1; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Epstein-Barr virus encoded RNA 1; 0 / Interferon Regulatory Factors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Viral; 0 / interferon regulatory factor-4; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


29. Nomura Y, Yoshida S, Karube K, Takeshita M, Hirose S, Nakamura S, Yoshino T, Kikuchi M, Ohshima K: Estimation of the relationship between caspase-3 expression and clinical outcome of Burkitt's and Burkitt-like lymphoma. Cancer Sci; 2008 Aug;99(8):1564-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of the relationship between caspase-3 expression and clinical outcome of Burkitt's and Burkitt-like lymphoma.
  • Burkitt's lymphoma and atypical Burkitt/Burkitt-like lymphoma (BL/BLL) are considered highly aggressive B-cell lymphomas with a rapid proliferative rate and high rate of apoptosis.
  • The aim of the present study was to confirm whether apoptotic and cell proliferative factors affect BL/BLL clinical outcomes.
  • [MeSH-major] Biomarkers, Tumor. Burkitt Lymphoma / genetics. Caspase 3 / metabolism. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / genetics. Cell Proliferation. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Gene Expression. Genes, bcl-2 / genetics. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Prednisone / therapeutic use. Prognosis. Retrospective Studies. Survival Rate. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18754867.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.4.22.- / Caspase 3; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


30. Fadiora SO, Mabayoje VO, Aderoumu AO, Adeoti ML, Olatoke SA, Oguntola AS: Generalised Burkitt's lymphoma involving both breasts--a case report. West Afr J Med; 2005 Jul-Sep;24(3):280-2
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generalised Burkitt's lymphoma involving both breasts--a case report.
  • BACKGROUND: Burkitt's lymphoma is a disease of children age ranging 8-10 years.
  • Lymphoma involving the breast is an unusual clinical entity, which is rarely distinguished preoperatively from other more common forms of breast cancer.
  • She was diagnosed histologically as primary breast Burkitt's lymphoma.
  • CONCLUSION: Compared with breast carcinoma, primary breast lymphoma is a rare disease but should be considered in the differential diagnosis of breast masses.
  • [MeSH-major] Breast Neoplasms / pathology. Burkitt Lymphoma / pathology. Pregnancy Complications, Neoplastic / pathology
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Female. Humans. Pregnancy. Pregnancy Trimester, Third

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16276714.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


31. Glasheen JJ, Sorensen MD: Burkitt's lymphoma presenting with lactic acidosis and hypoglycemia - a case presentation. Leuk Lymphoma; 2005 Feb;46(2):281-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma presenting with lactic acidosis and hypoglycemia - a case presentation.
  • We present what appears to be the first reported case of lactic acidosis and hypoglycemia in an adult patient with Burkitt's lymphoma.
  • Lactic acidosis and hypoglycemia are rare complications of non-Hodgkin's lymphoma (NHL) with only 26 and 8 previous reports, respectively.
  • Two prior cases of Burkitt's lymphoma-induced lactic acidosis have been reported (one child, one adult), both in the absence of hypoglycemia.
  • Thoracentesis and bone marrow studies revealed Burkitt's lymphoma.
  • [MeSH-major] Acidosis, Lactic / etiology. Burkitt Lymphoma / complications. Hypoglycemia / etiology


32. Savvari P, Matsouka C, Barbaroussi D, Christoulas D, Nikitas N, Dimopoulos MA, Papadimitriou CA: Burkitt's lymphoma in pregnancy with bilateral breast involvement: case report with review of the literature. Onkologie; 2010;33(8-9):461-4
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma in pregnancy with bilateral breast involvement: case report with review of the literature.
  • BACKGROUND: Burkitt's lymphoma (BL) in pregnancy presenting with breast involvement is a rare clinical entity, and only 13 cases have been reported so far.
  • After achieving a complete objective response, the patient received consolidation with high dose BEAM followed by autologous stem cell transplantation.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / therapy. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / therapy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / therapy
  • [MeSH-minor] Adult. Female. Humans. Postpartum Period. Pregnancy

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • [CommentIn] Onkologie. 2010;33(8-9):419 [20838055.001]
  • (PMID = 20838063.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


33. Khanna M, Buddhavarapu SR: Primary Burkitt's Lymphoma Of The Appendix Presenting As Acute Abdomen: A Case Report. J Radiol Case Rep; 2008;2(5):9-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary Burkitt's Lymphoma Of The Appendix Presenting As Acute Abdomen: A Case Report.
  • Burkitt's lymphoma is a high grade B-cell neoplasm.
  • Its non-endemic form typically presents as abdominal mass in children.
  • Clinical presentations like acute abdomen can be secondary to intestinal obstruction, intussusception or sometimes perforation.We describe here a case of an adult male with an unusual presentation of appendiceal Burkitt's lymphoma mimicking acute cholecystitis or appendicitis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22470604.001).
  • [ISSN] 1943-0922
  • [Journal-full-title] Journal of radiology case reports
  • [ISO-abbreviation] J Radiol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3303244
  • [Keywords] NOTNLM ; Appendicitis / Appendix / Burkitt’s lymphoma / CT / Cholecystitis / Lymphoma
  •  go-up   go-down


34. Degeorges S, Mesnil A, Marion-Audibert AM, Bouafia-Sauvy F, Berger F, Bancel B, Barnoud R, Rode A, Péré-Vergé D, Souquet JC: [Ano-rectal symptoms, related to Epstein-Barr Virus-Associated Burkitt's lymphoma in an immunocompetent patient]. Gastroenterol Clin Biol; 2007 Apr;31(4):442-4
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ano-rectal symptoms, related to Epstein-Barr Virus-Associated Burkitt's lymphoma in an immunocompetent patient].
  • [Transliterated title] Manifestations anorectales, en rapport avec un lymphome de Burkitt associé au virus Epstein Barr, chez une malade immunocompétente.
  • Final diagnosis confirmed by biopsy performed during rectosigmoidoscopy was an Epstein-Barr Virus-Associated Burkitt's lymphoma.
  • [MeSH-major] Burkitt Lymphoma
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Female. Humans. Immunocompetence. Magnetic Resonance Imaging. Rectum / pathology. Sigmoidoscopy. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483786.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


35. De Boer JD, Boellaard TN, Parkinson S, Blanchard E, Heij HA: Patient compliance in the treatment of Burkitt's lymphoma in rural Zambia: a retrospective study on 80 Burkitt's lymphoma patients in Katete, Zambia. Afr J Paediatr Surg; 2009 Jan-Jun;6(1):3-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient compliance in the treatment of Burkitt's lymphoma in rural Zambia: a retrospective study on 80 Burkitt's lymphoma patients in Katete, Zambia.
  • BACKGROUND: In African settings the treatment results of Burkitt's lymphoma (BL) seem to be less favourable compared with Western settings.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Health Services Accessibility. Patient Compliance
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Retrospective Studies. Rural Population. Treatment Outcome. Zambia

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661656.001).
  • [ISSN] 0974-5998
  • [Journal-full-title] African journal of paediatric surgery : AJPS
  • [ISO-abbreviation] Afr J Paediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


36. Gao J, Luo X, Tang K, Li X, Li G: Epstein-Barr virus integrates frequently into chromosome 4q, 2q, 1q and 7q of Burkitt's lymphoma cell line (Raji). J Virol Methods; 2006 Sep;136(1-2):193-9
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus integrates frequently into chromosome 4q, 2q, 1q and 7q of Burkitt's lymphoma cell line (Raji).
  • Epstein-Barr virus (EBV) integration into a Burkitt's lymphoma (BL) cell line (Raji) was investigated, using polymerase chain reaction (PCR), Southern hybridization, genomic library screening and fluorescence in situ hybridization (FISH).
  • Chromosomal integration of EBV DNA was detected in the Raji cell.
  • This study is the first comprehensive FISH analysis of EBV integration into the chromosomes of the Raji cell line.
  • The findings support the notion that EBV integrates into the Raji cell genome non-randomly.
  • [MeSH-major] Burkitt Lymphoma / virology. Herpesvirus 4, Human / genetics. Virus Integration
  • [MeSH-minor] Adult. Blotting, Southern. Cell Line. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 2. Chromosomes, Human, Pair 4. DNA, Viral / genetics. Female. Genomic Library. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Polymerase Chain Reaction. Proviruses / genetics. Viral Matrix Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16806502.001).
  • [ISSN] 0166-0934
  • [Journal-full-title] Journal of virological methods
  • [ISO-abbreviation] J. Virol. Methods
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  •  go-up   go-down


37. Suzuki O, Nozawa Y, Abe M: Loss of L-PHA-, PNA-, or ConA-reactive oligosaccharides is associated with a poor prognosis in human Burkitt's lymphoma. Oncol Rep; 2007 Apr;17(4):775-9
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of L-PHA-, PNA-, or ConA-reactive oligosaccharides is associated with a poor prognosis in human Burkitt's lymphoma.
  • The expression of cell surface oligosaccharides is associated with various biological phenomena.
  • To clarify the relationship between lectin binding and the survival of patients with Burkitt's lymphoma, tumor samples from nine patients with Burkitt's lymphoma were analyzed by lectin histochemistry.
  • Collectively, a loss of L-PHA-, PNA-, or ConA-reactive oligosaccharides is closely associated with a poor prognosis in patients with Burkitt's lymphoma.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Concanavalin A / chemistry. Oligosaccharides / analysis. Peanut Agglutinin / chemistry. Phytohemagglutinins / chemistry
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Humans. Immunohistochemistry. N-Acetylglucosaminyltransferases / analysis. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17342314.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Oligosaccharides; 0 / Peanut Agglutinin; 0 / Phytohemagglutinins; 11028-71-0 / Concanavalin A; EC 2.4.1.- / N-Acetylglucosaminyltransferases; EC 2.4.1.155 / alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase
  •  go-up   go-down


38. Takasu M, Takeshita S, Tanitame N, Tamura A, Mori M, Fujihara M, Ito K: Case report. Primary hypothalamic third ventriclular Burkitt's lymphoma: a case report with emphasis on differential diagnosis. Br J Radiol; 2010 Feb;83(986):e43-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report. Primary hypothalamic third ventriclular Burkitt's lymphoma: a case report with emphasis on differential diagnosis.
  • A patient with primary Burkitt-type lymphoma of the central nervous system is presented.
  • A hypothalamic-third ventricular tumour in a man 71 years of age was diagnosed histologically as Burkitt's lymphoma.
  • Primary Burkitt's lymphoma of the hypothalamic region is extremely rare and has not been previously reported in adults.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Glioma / diagnosis. Hypothalamic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Child. Child, Preschool. Diabetes Insipidus / diagnosis. Diabetes Insipidus / drug therapy. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Third Ventricle. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2001 Feb;23(2):130-3 [11216706.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Oct;21(9):1661-3 [11039346.001]
  • [Cites] AJR Am J Roentgenol. 2001 May;176(5):1319-26 [11312202.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Mar;23(3):364-7 [11901000.001]
  • [Cites] J Neurosurg. 2002 Jun;96(6):1127-9 [12066916.001]
  • [Cites] Neurocirugia (Astur). 2002 Aug;13(4):305-10 [12355653.001]
  • [Cites] Cancer. 1976 Mar;37(3):1500-7 [177169.001]
  • [Cites] Surg Neurol. 1984 Jan;21(1):23-9 [6359511.001]
  • [Cites] J Comput Assist Tomogr. 1984 Aug;8(4):645-7 [6736361.001]
  • [Cites] Acta Neuropathol. 1984;64(1):12-4 [6475493.001]
  • [Cites] Cancer. 1988 Dec 1;62(11):2461-5 [3179963.001]
  • [Cites] AJR Am J Roentgenol. 2005 May;184(5):1679-85 [15855138.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Nov-Dec;26(10):2446-54 [16286384.001]
  • [Cites] Afr Health Sci. 2007 Sep;7(3):166-75 [18052871.001]
  • [Cites] Cas Lek Cesk. 2008;147(11):569-73 [19097361.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):261-6 [10659013.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Mar;22(3):464-9 [11237967.001]
  • (PMID = 20139257.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3473536
  •  go-up   go-down


39. Shui RH, Lu HF, Zhu XZ: [Immunohistochemical study using T-cell lymphoma antibody 1 and CD44 in diagnosis of Burkitt's lymphoma]. Zhonghua Bing Li Xue Za Zhi; 2009 Nov;38(11):745-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical study using T-cell lymphoma antibody 1 and CD44 in diagnosis of Burkitt's lymphoma].
  • OBJECTIVE: To study the values of immunohistochemistry using T-cell lymphoma antibody (TCL) 1 and CD44 in the diagnosis of Burkitt's lymphoma.
  • METHODS: Immunohistochemical study for TCL1, CD44, CD10, bcl-2, bcl-6, c-myc and Ki-67 was performed on paraffin-embedded sections of lymphoma cases, including 25 cases of Burkitt's lymphoma and 25 cases of diffuse large B-cell lymphoma.
  • RESULTS: Burkitt's lymphoma commonly expressed TCL1 (96%, 24 cases), CD10 (88%, 22 cases), bcl-6 and c-myc (92%, 23 cases).
  • On the other hand, diffuse large B-cell lymphoma expressed CD44 (84%, 21 cases), CD10 (32%, 8 cases), bcl-6 (72%, 18 cases) and bcl-2 (72%, 18 cases).
  • CONCLUSION: Immunohistochemical staining for TCL1 and CD44 is a useful ancillary tool in the pathologic diagnosis of Burkitt's lymphoma which is also helpful for the differential diagnosis from diffuse large B-cell lymphoma.
  • [MeSH-major] Antigens, CD44 / metabolism. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / metabolism. Proto-Oncogene Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079013.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Proto-Oncogene Proteins; 0 / TCL1A protein, human
  •  go-up   go-down


40. Amusa YB, Adediran IA, Akinpelu VO, Famurewa OC, Olateju SO, Adegbehingbe BO, Komolafe EO, Faponle AF, Olasode BJ: Burkitt's lymphoma of the head and neck region in a Nigerian tertiary hospital. West Afr J Med; 2005 Apr-Jun;24(2):139-42
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma of the head and neck region in a Nigerian tertiary hospital.
  • BACKGROUND: Burkitt's lymphoma is endemic in Nigeria; it forms about 39% of all childhood cancers.
  • OBJECTIVE: This study is designed to look at the pattern of presentation of head and Neck Burkitt's lymphoma at a Nigerian Tertiary hospital and to evaluate current treatment modality.
  • DESIGN: It is a retrospective study of all confirmed Burkitt's lymphoma of the head and neck region seen at the Obafemi Awolowo University Teaching Hospital Ile Ife (OAUTHC) between 1986 and 2002.
  • PATIENTS AND METHODS: The medical records of all the patients with the histopathologically confirmed Burkitt's lymphoma over a 17-year period (1986-2002) were evaluated.
  • RESULTS: A total of 196 cases of Burkitt's lymphoma were seen over the period out of which 140 (71.4%) were in the head and neck region.
  • CONCLUSION: Head and neck remain the mostly affected parts in Burkitt's lymphoma in this environment.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Head and Neck Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Nigeria / epidemiology. Retrospective Studies. Surveys and Questionnaires. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] West Afr J Med. 2005 Jul-Sep;24(3):189. Adegbeingbe, OD [corrected to Adegbehingbe, BO]
  • (PMID = 16092315.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


41. Rastogi MV, Desai N, Quintos JB: Non-islet-cell tumor hypoglycemia and lactic acidosis in a child with congenital HIV and Burkitt's lymphoma. J Pediatr Endocrinol Metab; 2008 Aug;21(8):805-10
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-islet-cell tumor hypoglycemia and lactic acidosis in a child with congenital HIV and Burkitt's lymphoma.
  • BACKGROUND: Non-islet-cell tumor hypoglycemia (NICTH) is a rare cause of hypoglycemia associated with tumors of mesenchymal, epithelial, or hematopoietic origin.
  • Lactic acidosis is likewise an uncommon complication of hematological malignancy associated mainly with leukemia and lymphoma.
  • Most cases of NICTH and lactic acidosis have been described in the adult population.
  • We report a child with congenital HIV and AIDS who developed Burkitt's lymphoma, lactic acidosis and NICTH.
  • PATIENT: An 11 year-old boy with AIDS, cerebral palsy and seizure disorder presented with intractable hypoglycemia 12 days after diagnosis of Burkitt's lymphoma.
  • CONCLUSION: We present a case of lactic acidosis and NICTH in an 11 year-old boy with AIDS and Burkitts's lymphoma.
  • [MeSH-major] Acidosis, Lactic / complications. Acidosis, Lactic / diagnosis. Acquired Immunodeficiency Syndrome / complications. Burkitt Lymphoma / complications. Hypoglycemia / complications. Hypoglycemia / diagnosis


42. Orem J, Mbidde EK, Lambert B, de Sanjose S, Weiderpass E: Burkitt's lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci; 2007 Sep;7(3):166-75
HIV InSite. treatment guidelines - Malaria and HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma in Africa, a review of the epidemiology and etiology.
  • Burkitt's lymphoma (BL) was first described in Eastern Africa, initially thought to be a sarcoma of the jaw.
  • Shortly it became well known that this was a distinct form of Non Hodgkin's lymphoma.
  • [MeSH-major] Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / etiology
  • [MeSH-minor] Adolescent. Adult. Africa / epidemiology. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):481-5 [10508483.001]
  • [Cites] Lancet. 1991 May 18;337(8751):1190 [1673740.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(14):1878-85 [10711230.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):489-92 [11054682.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):622-7 [11340563.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):687-91 [11340573.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] Br J Cancer. 2003 May 19;88(10):1566-9 [12771923.001]
  • [Cites] J Ethnopharmacol. 2003 Sep;88(1):19-44 [12902048.001]
  • [Cites] J Ethnopharmacol. 2003 Oct;88(2-3):279-86 [12963156.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):803-21 [14871955.001]
  • [Cites] Toxicon. 2004 Sep 15;44(4):417-30 [15302524.001]
  • [Cites] Cancer. 2004 Sep 15;101(6):1420-7 [15368330.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Science. 1967 Sep 1;157(3792):1064-5 [6036237.001]
  • [Cites] J Virol. 1967 Aug;1(4):830-7 [4316231.001]
  • [Cites] J Natl Cancer Inst. 1971 Apr;46(4):861-71 [4324816.001]
  • [Cites] J Natl Cancer Inst. 1973 May;50(5):1163-73 [4351392.001]
  • [Cites] IARC Sci Publ. 1975;(11 Pt 2):3-16 [191375.001]
  • [Cites] Nature. 1979 Jul 19;280(5719):244-5 [221841.001]
  • [Cites] Lancet. 1981 Jul 18;2(8238):115-8 [6113482.001]
  • [Cites] Int J Cancer. 1982 Apr 15;29(4):397-400 [6282763.001]
  • [Cites] Cancer Lett. 1983 Jun;19(2):199-205 [6309363.001]
  • [Cites] Lancet. 1987 May 30;1(8544):1257-8 [2884382.001]
  • [Cites] Am J Epidemiol. 1989 Apr;129(4):740-52 [2923122.001]
  • [Cites] Trop Geogr Med. 1990 Jul;42(3):255-60 [2293434.001]
  • [Cites] Eur J Cancer. 1991;27(4):504-9 [1827731.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1991 Summer;13(2):222-46 [2069232.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1356-60 [1873787.001]
  • [Cites] Cent Afr J Med. 1992 Jan;38(1):17-25 [1633615.001]
  • [Cites] Curr Opin Oncol. 1992 Oct;4(5):883-93 [1457503.001]
  • [Cites] Semin Cancer Biol. 1992 Oct;3(5):285-95 [1335792.001]
  • [Cites] Br J Cancer. 1993 Dec;68(6):1232-5 [8260378.001]
  • [Cites] Lancet. 1995 May 27;345(8961):1378-9 [7752795.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492 [9705682.001]
  • [Cites] J Virol. 1998 Oct;72(10):8105-14 [9733851.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] Br J Surg. 1958 Nov;46(197):218-23 [13628987.001]
  • [Cites] Cancer. 1961 Mar-Apr;14:258-69 [14448554.001]
  • [Cites] Lancet Oncol. 2004 Dec;5(12):738-46 [15581545.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]
  • [Cites] AIDS. 1999 Dec 24;13(18):2563-70 [10630526.001]
  • (PMID = 18052871.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Uganda
  • [Number-of-references] 50
  • [Other-IDs] NLM/ PMC2269718
  •  go-up   go-down


43. Sun XF, Zhen ZJ, Lui DG, Xia Y, He YJ, Wang ZH, Lin JY, Guan ZZ: Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol. Eur J Haematol; 2006 Nov;77(5):365-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol.
  • OBJECTIVES: This study was designed to evaluate the efficacy and toxicity of the modified B-Non-Hodgkin's Lymphoma (NHL)-Berlin-Frankfurt-Münster (BFM)-90-based protocol in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma.
  • Of these patients, 22 (40%) had Burkitt's lymphoma (BKL), 22 (40%) had diffuse large B-cell lymphoma (DLBL) and 11 (20%) had anaplastic large T-cell lymphoma (ALCL).
  • CONCLUSIONS: This modified NHL-BFM-90 protocol is very effective for Chinese children and adolescents with BKL and large cell lymphomas, and represented an increase in the cure rates in childhood NHL in China.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Burkitt Lymphoma / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Asparaginase / administration & dosage. Asparaginase / adverse effects. Child. Child, Preschool. China. Daunorubicin / administration & dosage. Daunorubicin / adverse effects. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Male. Mucositis / chemically induced. Prednisone / administration & dosage. Prednisone / adverse effects. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879606.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


44. Sun XF, Zhen ZJ, Liu DG, Xia Y, Xiang XJ, Chen XQ, Ling JY, Zheng L, Luo WB, Lin H, He YJ, Guan ZZ: [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents]. Ai Zheng; 2007 Dec;26(12):1339-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
  • BACKGROUND & OBJECTIVE: Burkitt's lymphoma is an aggressive non-Hodgkin's lymphoma (NHL) and often involves bone marrow and central nerve system.
  • The efficacy of CHOP regimen on Burkitt's lymphoma is poor.
  • This study was to evaluate the efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in children and adolescents, and observe the survival status.
  • 2006, 31 untreated Burkitt's lymphoma patients aged less than 20 were enrolled.
  • CONCLUSIONS: Modified B-NHL-BFM-90 protocol can improve the responses and survival of Burkitt's lymphoma in Chinese children and adolescents, with tolerable toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Infant. L-Lactate Dehydrogenase / blood. Leukopenia / chemically induced. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasm Staging. Remission Induction. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076797.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


45. Montoto S, Wilson J, Shaw K, Heath M, Wilson A, McNamara C, Orkin C, Nelson M, Johnson M, Bower M, Cwynarski K: Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. AIDS; 2010 Mar 27;24(6):851-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma.
  • OBJECTIVE AND DESIGN: : To retrospectively describe the recovery of cellular immunity and the clinical outcome of 30 patients with HIV-associated Burkitt's lymphoma (HIV-BL), who were treated with the intensive chemotherapy CODOX-M/IVAC and HAART as part of their standard care.
  • The median CD4 cell count at diagnosis of HIV-BL was 171/ml (range: 4-848) and the plasma HIV viral load was undetectable in five of 29 patients.
  • Viral load was undetectable in 88% and CD4 cell count more than 200/ml in 58% of patients assessed 6 months after completing chemotherapy, and in 87 and 80% at 12 months, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Burkitt Lymphoma / drug therapy. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Aged. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage


46. Kravchenko SK, Bariakh EA, Zamiatina VI, Perestoronina TN, Fink OS, Gubkin AV, Egorova EK, Zvonkov EE, Iliushkina EA, Krasil'nikova BB, Morozova AK, Vorob'ev IA, Kaplanskaia IB, Kliasova GA, Obukhova TN, Kremenetskaia AM, Vorob'ev AI: [High-dose therapy of Burkitt's lymphoma in patients over 40 years of age]. Ter Arkh; 2008;80(7):9-18
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High-dose therapy of Burkitt's lymphoma in patients over 40 years of age].
  • AIM: To analyse efficacy and tolerance of high-dose polychemotherapy (PCT) of Berkitt's lymphoma (BL) in patients aged over 40 years.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adult. Biopsy. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18763588.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


47. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM: AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol; 2005 Jul 1;23(19):4430-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
  • PURPOSE: To compare outcomes of patients with HIV-Burkitt's lymphoma (HIV-BL) and HIV-diffuse large-cell lymphoma (HIV-DLCL) after treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or M-BACOD (methotrexate, bleomycin, cyclophosphamide, etoposide) in pre-highly active antiretroviral therapy (HAART) versus HAART eras.
  • PATIENTS AND METHODS: Three hundred sixty-three patients with AIDS-related lymphoma diagnosed from 1982 to 2003 were reviewed retrospectively, including 262 in the pre-HAART (HIV-BL, 117; HIV-DLCL, 145) and 101 in the HAART era (HIV-BL, 18; HIV-DLCL, 83).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Bleomycin / therapeutic use. Burkitt Lymphoma / mortality. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Leucovorin / therapeutic use. Lymphoma, AIDS-Related / mortality. Lymphoma, Large B-Cell, Diffuse / mortality. Methotrexate / therapeutic use. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Nov 20;23(33):8538-40; author reply 8540-1 [16293885.001]
  • [CommentIn] J Clin Oncol. 2005 Nov 1;23(31):8132-3; author reply 8133-4 [16258119.001]
  • (PMID = 15883411.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; M-BACOD protocol
  •  go-up   go-down


48. Lehmann C, Wyen C, Hoffmann C, Fätkenheuer G: Successful administration of aggressive chemotherapy concomitant to tuberculostatic and highly active antiretroviral therapy in a patient with AIDS-related Burkitt's lymphoma. HIV Med; 2005 Jan;6(1):51-3
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful administration of aggressive chemotherapy concomitant to tuberculostatic and highly active antiretroviral therapy in a patient with AIDS-related Burkitt's lymphoma.
  • Treatment of AIDS-related malignant lymphoma (ARL) remains a therapeutic challenge.
  • We report the case of a 38-year-old man with advanced HIV-1 infection, pulmonary tuberculosis and Burkitt's lymphoma.
  • Six months later, the patient achieved not only a complete remission of Burkitt's lymphoma and sustained viral suppression, but also a full recovery from tuberculosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Antitubercular Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] AIDS-Related Opportunistic Infections / complications. AIDS-Related Opportunistic Infections / drug therapy. Adult. Humans. Male. Tuberculosis, Pulmonary / complications. Tuberculosis, Pulmonary / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670254.001).
  • [ISSN] 1464-2662
  • [Journal-full-title] HIV medicine
  • [ISO-abbreviation] HIV Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


49. Bellier C, Khellaf M, Lambotte O, Godeau B: [Burkitt's lymphoma in a patient with systemic lupus erythematosus treated with immunosuppressive drugs. A case report]. Rev Med Interne; 2006 Mar;27(3):244-7
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Burkitt's lymphoma in a patient with systemic lupus erythematosus treated with immunosuppressive drugs. A case report].
  • [Transliterated title] Lymphome de Burkitt au cours d'un lupus systémique traité par immunosuppresseurs. A propos d'un cas.
  • However, the pathophysiological link between lymphoma and SLE is still a matter of debate.
  • We report a new case of Burkitt's lymphoma occurring in a patient treated with immunosuppressive drugs for SLE.
  • A bone marrow biopsy revealed Burkitt's lymphoma.
  • CONCLUSION: This is the third case reported of Burkitt's lymphoma occurring in SLE.
  • Here we discuss the data of the literature and the possible pathophysiological links between Burkitt's lymphoma and SLE.


50. Chishima F, Hayakawa S, Ohta Y, Sugita K, Yamazaki T, Sugitani M, Yamamoto T: Ovarian Burkitt's lymphoma diagnosed by a combination of clinical features, morphology, immunophenotype, and molecular findings and successfully managed with surgery and chemotherapy. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:337-43
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian Burkitt's lymphoma diagnosed by a combination of clinical features, morphology, immunophenotype, and molecular findings and successfully managed with surgery and chemotherapy.
  • Ovarian involvement as an initial manifestation of lymphoma, without detectable extraovarian disease, is a rare occurrence.
  • The diagnosis of ovarian lymphoma is almost invariably unsuspected until the tumor has been examined histologically.
  • Presence of abnormal lymphoid cells in pleural effusion led to presurgical assumption that the pelvic mass noted on computerized tomography examination might be an ovarian lymphoma.
  • Clinical, histologic, and molecular examination revealed Burkitt's lymphoma of the ovary with c-myc gene rearrangement and mRNA expression of multiple cytokines.
  • Immunophenotype and molecular findings allowed reliable discrimination of Burkitt's lymphoma from diffuse large B-cell lymphoma and other lymphomas.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / therapy. Herpesvirus 4, Human / isolation & purification. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Cytokines / analysis. Doxorubicin / administration & dosage. Female. Genes, myc / genetics. Gynecologic Surgical Procedures. Humans. Prednisolone / administration & dosage. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515618.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Cytokines; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


51. Kiefer T, Schüler F, Knopp A, Wimmer M, Hirt C, Schaefer HE, Dölken G: A human Burkitt's lymphoma cell line carrying t(8;22) and t(14;18) translocations. Ann Hematol; 2007 Nov;86(11):821-30
Cellosaurus - a cell line knowledge resource. culture/stock collections - DoGKiT (CVCL_2023) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A human Burkitt's lymphoma cell line carrying t(8;22) and t(14;18) translocations.
  • We describe the first cell line exhibiting t(14;18) and t(8;22), which will enable us to study the interactions of bcl-2 and c-myc systematically.
  • Cell culture was started with circulating lymphoma cells from the peripheral blood of an adult male Caucasian patient with Burkitt's lymphoma after the second relapse.
  • The cells grew spontaneously without cytokines, fulfilled all criteria of a cell line and were analysed.
  • An Epstein-Barr virus (EBV) genome-negative cell line (DoGKiT) has been established.
  • The combination of t(8;22)(q24;q11), a variant translocation of Burkitt's lymphoma and t(14;18)(q32;q21), typical for follicular lymphoma (FL), was confirmed by FISH and SKY-analysis.
  • Surface marker studies of the cell line showed that the cells were positive for CALLA (CD10), CD19, cyCD22, cyCD79a and HLA-DR and negative for TdT, IgM, CD5 and CD23.
  • To our knowledge, this is the first established cell line carrying these two translocations.
  • In contrast to already established cell lines carrying the more common combination of t(8;14)(q24;q32) and t(14;18)(q32;q21) with both IgH alleles being involved in translocations, the cell line DoGKiT carries only one translocated IgH allele.
  • This cell line may serve as an important tool in the study of the combination of the chromosomal translocations t(14;18) and t(8;22) and in molecular genetic studies of transformed FL.
  • [MeSH-major] Burkitt Lymphoma / genetics. Cell Line, Tumor. Genes, bcl-2 / genetics. Genes, myc / genetics. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17622530.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


52. Fujishima N, Fujishima M, Inomata M, Yamanaka Y, Saitoh K, Kameoka Y, Yoshioka T, Saitoh H, Takahashi N, Hirokawa M, Sawada K: [Early relapse of Burkitt's lymphoma with t(8;14) and t(14;18) after rituximab-combined CODOX-M and IVAC therapy]. Rinsho Ketsueki; 2007 Apr;48(4):326-31
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early relapse of Burkitt's lymphoma with t(8;14) and t(14;18) after rituximab-combined CODOX-M and IVAC therapy].
  • Laboratory data revealed leukocytosis with a white blood cell count of 18200/microl, 25% atypical cells and an LDH of 13410 IU/l.
  • The patient was diagnosed as having Burkitt's lymphoma (BL) with t(8;14) and t(14;18).
  • Although CODOX-M and IVAC therapy combined with rituximab achieved complete remission, she died of rapid progressive disease during whole brain irradiation before autologous peripheral blood stem cell transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / genetics. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 8 / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Female. Humans. Ifosfamide / administration & dosage. Methotrexate / administration & dosage. Recurrence. Remission Induction. Rituximab. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17515125.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol; IVAC protocol
  •  go-up   go-down


53. Moleti ML, Testi AM, Giona F, Malandruccolo L, Pescarmona E, Martino P, Paoloni F, Barberi W, Palumbo G, Mandelli F, Foa R: CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience. Leuk Lymphoma; 2007 Mar;48(3):551-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience.
  • During the last 15 years, we have used the National Cancer Institute (NCI) 89-C-41 protocol in patients aged younger than 21 years with Burkitt's leukemia/lymphoma (BLL) and diffuse large B-cell lymphoma (DLBCL).
  • Thirty-five patients entered the study: 32 (91%) achieved complete remission (CR); three were non-responders and died and one patient died in CR.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Leukemia / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Ifosfamide / therapeutic use. Male. Methotrexate / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Neoplasm Staging. Prognosis. Risk Factors. Survival Rate. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454598.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol; IVAC protocol
  •  go-up   go-down


54. Matis S, Mariani MR, Cutrona G, Cilli M, Piccardi F, Daga A, Damonte G, Millo E, Moroni M, Roncella S, Fedeli F, Boffa LC, Ferrarini M: PNAEmu can significantly reduce Burkitt's lymphoma tumor burden in a SCID mice model: cells dissemination similar to the human disease. Cancer Gene Ther; 2009 Oct;16(10):786-93
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PNAEmu can significantly reduce Burkitt's lymphoma tumor burden in a SCID mice model: cells dissemination similar to the human disease.
  • In human Burkitt's Lymphoma (BL) BRG cells, a t(8;14) translocation, placing c-myc near the Emu enhancer of the H chain locus, causes tumor expansion.
  • BRG-BL cells transfected with the luciferase gene were inoculated intravenously into SCID mice resulting in a preferential expansion, similar to the one of human adult patients, in the abdominal cavity, central nervous system and bone marrow.
  • Histological and immunohistochemical studies showed, only in PNAEmu-treated mice, a substantially reduced BL cell growth at the major sites of invasion and vast areas of necrosis in the lymphomatous tissues, with concomitant c-myc expression downregulation.
  • Altogether, the data support the therapeutic potential of PNAEmu in human adult BL.
  • [MeSH-major] Burkitt Lymphoma / drug therapy. Peptide Nucleic Acids / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Transformation, Viral. Female. Humans. Luciferases, Firefly / biosynthesis. Luciferases, Firefly / genetics. Luminescent Measurements. Mice. Mice, SCID. Proto-Oncogene Proteins c-myc / biosynthesis. Proto-Oncogene Proteins c-myc / genetics. Transfection. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19363465.001).
  • [ISSN] 1476-5500
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Peptide Nucleic Acids; 0 / Proto-Oncogene Proteins c-myc; EC 1.13.12.7 / Luciferases, Firefly
  •  go-up   go-down


55. Jarrett RF: Viruses and lymphoma/leukaemia. J Pathol; 2006 Jan;208(2):176-86
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viruses and lymphoma/leukaemia.
  • The human T-cell leukaemia virus type 1 causes adult T-cell leukaemia and the Epstein-Barr virus is associated with Burkitt's lymphoma, lymphomas in immunosuppressed people, and Hodgkin lymphoma.
  • Individuals infected with the human immunodeficiency virus are at greatly increased risk of developing lymphoma but here the mechanism of lymphomagenesis is indirect.
  • Recent data suggest that hepatitis C virus infection is also associated with an increased incidence of lymphoma, whereas data relating to SV40 remain controversial.
  • [MeSH-major] Leukemia / virology. Lymphoma / virology
  • [MeSH-minor] Adult. Burkitt Lymphoma / genetics. Burkitt Lymphoma / immunology. Burkitt Lymphoma / virology. HIV / immunology. Hepacivirus / immunology. Herpesvirus 1, Cercopithecine / immunology. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / immunology. Hodgkin Disease / genetics. Hodgkin Disease / immunology. Hodgkin Disease / virology. Human T-lymphotropic virus 1 / genetics. Human T-lymphotropic virus 1 / immunology. Humans. Simian virus 40 / immunology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • [CommentIn] J Pathol. 2006 Jul;209(3):420-1; author reply 422-4 [16639695.001]
  • (PMID = 16362996.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 105
  •  go-up   go-down


56. Oriol A, Ribera JM, Brunet S, del Potro E, Abella E, Esteve J: Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica; 2005 Jul;90(7):990-2
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study.
  • Short, intensive cycles of chemotherapy have resulted in improved survival in BurkittOs lymphoma/leukemia (BL) in adults.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Leukemia / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Adult. Aged. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Dexamethasone / therapeutic use. Disease-Free Survival. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Ifosfamide / therapeutic use. Leucovorin / therapeutic use. Male. Methotrexate / therapeutic use. Middle Aged. Prednisone / therapeutic use. Treatment Outcome. Vincristine / therapeutic use


57. Valnet-Rabier MB, Challier B, Thiebault S, Angonin R, Margueritte G, Mougin C, Kantelip B, Deconinck E, Cahn JY, Fest T: c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome. Br J Haematol; 2005 Mar;128(6):767-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome.
  • The World Health Organization Classification of Lymphoid Neoplasms identifies Burkitt's lymphoma/leukaemia (BL) as a single entity, characterized by unique clinical and genetic features that require specific high intensity chemotherapy regimens.
  • [MeSH-major] Burkitt Lymphoma / metabolism. Intracellular Signaling Peptides and Proteins / metabolism
  • [MeSH-minor] Adult. Antigens, CD95 / metabolism. Apoptosis. CASP8 and FADD-Like Apoptosis Regulating Protein. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755279.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / CASP8 and FADD-Like Apoptosis Regulating Protein; 0 / CFLAR protein, human; 0 / Intracellular Signaling Peptides and Proteins
  •  go-up   go-down


58. García Ortiz LM, Jaume Anselmi F, Ramírez Rivera J, Casiano Quiles W, Márquez Santiago R: Non-Hodgkin's lymphoma presenting as ulcerative colitis. Bol Asoc Med P R; 2006 Apr-Jun;98(2):140-3
MedlinePlus Health Information. consumer health - Ulcerative Colitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma presenting as ulcerative colitis.
  • High-grade Non-Hodgkin's lymphomas are very aggressive type of malignancies.
  • We report a high grade small B-cell (Burkitt's like) Non-Hodgkin's lymphoma that initially was considered and treated as ulcerative colitis without improvement or resolution of symptoms for nine months.
  • [MeSH-major] Colitis, Ulcerative / etiology. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19606804.001).
  • [ISSN] 0004-4849
  • [Journal-full-title] Boletín de la Asociación Médica de Puerto Rico
  • [ISO-abbreviation] Bol Asoc Med P R
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


59. Yeole BB: Trends in the incidence of Non-Hodgkin's lymphoma in India. Asian Pac J Cancer Prev; 2008 Jul-Sep;9(3):433-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in the incidence of Non-Hodgkin's lymphoma in India.
  • Non-Hodgkin's lymphoma is the 11th most common cancer in terms of incidence.
  • It is not a single cancer, but rather a wide group of cancers (including entities such as Burkitt's lymphoma and diffuse large B-cell lymphoma), each with a district geographical distribution, development path, age profile and prognosis.
  • Non-Hodgkin's lymphoma is increasing in incidence world wide.
  • On this background, in this paper an attempt has been made to study the trends in Non-Hodgkin's lymphoma in various Indian populations in both sexes.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / epidemiology. Female. Health Surveys. Humans. Incidence. India / epidemiology. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / epidemiology. Male. Middle Aged. Registries. Sex Distribution. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18990016.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


60. Kang KM, Song DS, Park JM, Jung CK, Hong YS, Kang MW, Park CW: Four cases of non-Hodgkin's lymphoma in AIDS patients. Korean J Intern Med; 2006 Dec;21(4):266-74
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four cases of non-Hodgkin's lymphoma in AIDS patients.
  • The incidence of opportunistic infection has decreased since the introduction of highly active antiretroviral therapy, so lymphoma is now far and away the most lethal complication of acquired immunodeficiency syndrome.
  • The first patient was a 37 year old male who presented with left sided hemiplegia due to CNS lymphoma.
  • The second patient was a 40 year old male who was admitted because of jaundice; he was diagnosed as having lymphoma that exclusively involved the liver.
  • The third patient was a 38-year-old male who presented with palpable mass in the left cervical region, which was diagnosed as lymphoma.
  • Above three cases were confirmed as diffuse large B cell lymphoma.
  • The fourth patient presented with a protruding swollen chest wall mass on the right side of his chest, this was determined pathologically to be the Burkitt's type.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adult. Aged. Biopsy. Diagnosis, Differential. Fatal Outcome. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):863-73 [11298581.001]
  • [Cites] Korean J Intern Med. 2001 Mar;16(1):1-7 [11417298.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):430-5 [11433410.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] Leuk Lymphoma. 2003 Feb;44(2):349-51 [12688356.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1981 Jun 5;30(21):250-2 [6265753.001]
  • [Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]
  • [Cites] JAMA. 1989 Feb 3;261(5):719-24 [2536124.001]
  • [Cites] Ann Intern Med. 1990 Aug 15;113(4):276-82 [1973886.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Leuk Lymphoma. 1998 Aug;30(5-6):515-24 [9711914.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):481-5 [10508483.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]
  • (PMID = 17249512.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3891035
  •  go-up   go-down


61. Jacobsen E, LaCasce A: Update on the therapy of highly aggressive non-Hodgkin's lymphoma. Expert Opin Biol Ther; 2006 Jul;6(7):699-708
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the therapy of highly aggressive non-Hodgkin's lymphoma.
  • This review focuses on the current understanding of the biology of highly aggressive non-Hodgkin's lymphomas, such as Burkitt's lymphoma, lymphoblastic lymphoma and adult T cell lymphoma/leukaemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma. Lymphoma, Non-Hodgkin. Lymphoma, T-Cell. Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adult. Child. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16805709.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 95
  •  go-up   go-down


62. Engels EA: Infectious agents as causes of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev; 2007 Mar;16(3):401-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infectious agents as causes of non-Hodgkin lymphoma.
  • Among exposures presently viewed as possible etiologic factors in non-Hodgkin lymphoma (NHL), infections are close to being regarded as established causes.
  • Lymphocyte-transforming viruses include Epstein Barr virus (linked to Burkitt's lymphoma, NHLs in immunosuppressed individuals, and extranodal natural killer/T-cell NHL), human herpesvirus 8 (primary effusion lymphoma), and human T lymphotropic virus type I (adult T-cell leukemia/lymphoma).
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / virology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337646.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


63. Schmitz N, Buske C, Gisselbrecht C: Autologous stem cell transplantation in lymphoma. Semin Hematol; 2007 Oct;44(4):234-45
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation in lymphoma.
  • High-dose therapy (HDT) followed by autologous transplantation of hematopoietic stem cells (ASCT) is frequently performed in patients with lymphoma.
  • Patients with indolent or aggressive B-cell lymphoma may benefit from HDT/ASCT if considered as part of first-line therapy or at the time of relapse.
  • Because data on patients with less frequent entities like mantle cell lymphoma, T-cell lymphoma, Burkitt's lymphoma, or lymphoblastic lymphoma are insufficient, the role of HDT/ASCT needs further study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma / drug therapy. Lymphoma / surgery. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / administration & dosage. Burkitt Lymphoma / mortality. Burkitt Lymphoma / therapy. Combined Modality Therapy. Disease-Free Survival. Evidence-Based Medicine. Hodgkin Disease / mortality. Hodgkin Disease / therapy. Humans. Lymphoma, Follicular / mortality. Lymphoma, Follicular / therapy. Lymphoma, Mantle-Cell / mortality. Lymphoma, Mantle-Cell / therapy. Middle Aged. Transplantation, Autologous / utilization. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961722.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 53
  •  go-up   go-down


64. Kaaya EE, Castaños-Velez E, Ekman M, Mwakigonja A, Carneiro P, Lema L, Kitinya J, Linde A, Biberfeld P: AIDS and non AIDS-related malignant lymphoma in Tanzania. Afr Health Sci; 2006 Jun;6(2):69-75
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS and non AIDS-related malignant lymphoma in Tanzania.
  • BACKGROUND: Malignant lymphoma (ML) in HIV patients, are second in frequency to Kaposi's sarcoma (AKS) as AIDS-defining tumors.
  • In Africa the frequency of AIDS-related lymphoma (ARL) is rare and the findings are controversial.
  • Both retrospective and prospective lymphoma cases were classified according to the revised European-American (REAL) classification.
  • OBJECTIVES: To determine the frequency and type of AIDS and non-AIDS related malignant lymphoma in Tanzania and a possible co-association with KSHV/HHV-8 and EBV.
  • The tumors were classified as Burkitt's (6), diffuse large cell (10), precursor-B lymphoblastic (1) and Hodgkin's disease (5) from HIV positive and negative patients.
  • Ten (40%) high grade ML and three Hodgkin's lymphoma from HIV patients had HHV-8 DNA.
  • These findings were not related to age, sex or type of lymphoma.
  • There was no association of HHV-8 with the lymphoma cells.
  • CONCLUSIONS: This study suggests an overall increased frequency of ML patients infected with HHV-8 in Tanzania particularly in HIV patients which may result from the well established high HHV-8 prevalence in the general population, but HHV-8 was not associated with ARL pathogenesis as reflected by lack of tumor cell infection.
  • [MeSH-major] Lymphoma / epidemiology. Lymphoma / pathology. Lymphoma, AIDS-Related / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / pathology. Child. Child, Preschool. Developing Countries. Female. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification. Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Humans. Immunohistochemistry. In Situ Hybridization. Incidence. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Polymerase Chain Reaction. Registries. Retrospective Studies. Risk Assessment. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / pathology. Sarcoma, Kaposi / virology. Survival Analysis. Tanzania / epidemiology. Young Adult

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):79-88 [9709308.001]
  • [Cites] Br J Cancer. 1997;75(11):1704-7 [9184191.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]
  • [Cites] Curr HIV/AIDS Rep. 2004 Apr;1(1):5-11 [16091217.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Scand J Infect Dis. 1994;26(6):749-52 [7747100.001]
  • [Cites] Int J Cancer. 1995 May 16;61(4):574-9 [7759163.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Nov 1;10(3):295-305 [7552491.001]
  • [Cites] AIDS. 2002 Mar 8;16(4):597-603 [11873003.001]
  • [Cites] J Med Virol. 2002 Oct;68(2):264-7 [12210417.001]
  • [Cites] Lancet Oncol. 2003 Feb;4(2):110-9 [12573353.001]
  • [Cites] Rev Clin Exp Hematol. 2003 Dec;7(4):375-405 [15129649.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]
  • [Cites] N Engl J Med. 1985 Dec 19;313(25):1564-71 [2999595.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Science. 1995 Apr 28;268(5210):582-3 [7725108.001]
  • [Cites] Nat Med. 1995 Jul;1(7):707-8 [7585156.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]
  • [Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):272-3 [8532016.001]
  • [Cites] Arch Intern Med. 1996 Jan 22;156(2):202-4 [8546554.001]
  • [Cites] Br J Haematol. 1995 Dec;91(4):918-20 [8547139.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):221-9 [8607449.001]
  • [Cites] Blood. 1996 May 1;87(9):3903-9 [8611719.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] J Mol Med (Berl). 1995 Dec;73(12):603-9 [8825757.001]
  • [Cites] AIDS. 1996 Aug;10(9):951-8 [8853727.001]
  • [Cites] J Virol. 1997 Mar;71(3):2505-11 [9032391.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • (PMID = 16916294.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Uganda
  • [Other-IDs] NLM/ PMC1831982
  •  go-up   go-down


65. Musallam KM, Hatoum HA, Barada K, Taher AT, Salem ME, Malek EM, Shamseddine AI: Primary colorectal lymphoma. Med Oncol; 2010 Jun;27(2):249-54
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary colorectal lymphoma.
  • Colonoscopy was performed for eight patients with non-specific gross tumor characteristics.
  • Three patients had Burkitt's and six had diffuse large B-Cell lymphomas.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / therapy. Lymphoma / diagnosis. Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Registries. Retrospective Studies. Survival Rate / trends

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19301158.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Karaosmanoglu D, Karcaaltincaba M, Oguz B, Akata D, Ozmen M, Akhan O: CT findings of lymphoma with peritoneal, omental and mesenteric involvement: peritoneal lymphomatosis. Eur J Radiol; 2009 Aug;71(2):313-7
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT findings of lymphoma with peritoneal, omental and mesenteric involvement: peritoneal lymphomatosis.
  • PURPOSE: We aimed to describe computed tomography (CT) findings in patients with peritoneal, omental and mesenteric lymphoma involvement.
  • MATERIALS AND METHODS: We searched our archive retrospectively to find out patients with peritoneal, omental and mesenteric lymphoma involvement.
  • We found 16 patients with non-Hodgkin lymphoma meeting these criteria.
  • RESULTS: There were 14 males and 2 females with peritoneal and/or mesenteric and omental lymphoma involvement.
  • Subgroups of non-Hodgkin lymphoma were diffuse large B-cell lymphoma (n=11), small cell lymphocytic lymphoma (n=2), small cleaved cell lymphoma (n=1), T-cell lymphoma (n=1) and Burkitt's lymphoma (n=1).
  • CONCLUSION: Peritoneal involvement can be seen in many subtypes of lymphoma and most frequently in diffuse large B-cell lymphoma.
  • [MeSH-major] Lymphoma / radiography. Mesentery / radiography. Omentum / radiography. Peritoneal Neoplasms / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18513906.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


67. Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos G, Cheson BD, Bartlett NL, Cancer and Leukemia Group B: Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906. Leuk Lymphoma; 2006 Aug;47(8):1511-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906.
  • Patients with relapsed or refractory aggressive non-Hodgkin's lymphomas (NHL) were eligible for this phase II study of doxorubicin 25 mg/m2 intravenous (IV) on day 1 and topotecan 1.75 mg/m2/day IV on days 3 - 5, every 21 days.
  • The patients had received a median of two (range one to five) prior regimens, including five patients with a prior stem cell transplant.
  • Both patients achieving a complete remission had Burkitt's lymphoma.
  • The activity in Burkitt's lymphoma should be investigated further.
  • [MeSH-major] Doxorubicin / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Salvage Therapy / methods. Topotecan / administration & dosage
  • [MeSH-minor] Adult. Aged. Burkitt Lymphoma / drug therapy. Disease-Free Survival. Enzyme Inhibitors / administration & dosage. Enzyme Inhibitors / therapeutic use. Female. Humans. Male. Middle Aged. Recurrence. Remission Induction. Topoisomerase I Inhibitors

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966261.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA07968; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA12046; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA86726
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Topoisomerase I Inhibitors; 7M7YKX2N15 / Topotecan; 80168379AG / Doxorubicin
  •  go-up   go-down


68. Shukla K, Patel T, Shukla J, Palanki S: Primary gastrointestinal lymphoma--a clinicopathologic study. Indian J Pathol Microbiol; 2007 Apr;50(2):296-9
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal lymphoma--a clinicopathologic study.
  • Gastrointestinal tract is the most common site for the development ofextra nodal lymphoma.
  • Out of 25 cases of primary GI lymphoma, nine cases of gastric lymphoma, nine cases of small intestinal lymphoma and seven cases of large intestinal lymphoma were identified.
  • Diffuse large B-cell type and Burkitt's lymphoma were the most common histologic variants, accounting for equal proportions (36% each).
  • 18 cases of GI lymphoma were evaluable, and out of these, 66.6% (11 cases) attained complete remission with a median follow up time of 12 months.
  • Clinical and histopathologic characteristics and prognosis of our cases with primary gastrointestinal lymphoma were usually similar to the cases in western countries with some differences in the incidence and histologic subtypes.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Helicobacter Infections / diagnosis. Helicobacter pylori / isolation & purification. Humans. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / therapy. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883049.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


69. Mozos A, Royo C, Hartmann E, De Jong D, Baró C, Valera A, Fu K, Weisenburger DD, Delabie J, Chuang SS, Jaffe ES, Ruiz-Marcellan C, Dave S, Rimsza L, Braziel R, Gascoyne RD, Solé F, López-Guillermo A, Colomer D, Staudt LM, Rosenwald A, Ott G, Jares P, Campo E: SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica; 2009 Nov;94(11):1555-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype.
  • BACKGROUND: Cyclin D1-negative mantle cell lymphoma is difficult to distinguish from other small B-cell lymphomas.
  • The clinical and pathological characteristics of patients with this form of lymphoma have not been well defined.
  • Overexpression of the transcription factor SOX11 has been observed in conventional mantle cell lymphoma.
  • The aim of this study was to determine whether this gene is expressed in cyclin D1-negative mantle cell lymphoma and whether its detection may be useful to identify these tumors.
  • DESIGN AND METHODS: The microarray database of 238 mature B-cell neoplasms was re-examined.
  • SOX11 protein expression was investigated immunohistochemically in 12 cases of cyclin D1-negative mantle cell lymphoma, 54 cases of conventional mantle cell lymphoma, and 209 additional lymphoid neoplasms.
  • RESULTS: SOX11 mRNA was highly expressed in conventional and cyclin D1-negative mantle cell lymphoma and in 33% of the cases of Burkitt's lymphoma but not in any other mature lymphoid neoplasm.
  • SOX11 nuclear protein was detected in 50 cases (93%) of conventional mantle cell lymphoma and also in the 12 cyclin D1-negative cases of mantle cell lymphoma, the six cases of lymphoblastic lymphomas, in two of eight cases of Burkitt's lymphoma, and in two of three T-prolymphocytic leukemias but was negative in the remaining lymphoid neoplasms.
  • Cyclin D2 and D3 mRNA levels were significantly higher in cyclin D1-negative mantle cell lymphoma than in conventional mantle cell lymphoma but the protein expression was not discriminative.
  • The clinico-pathological features and outcomes of the patients with cyclin D1-negative mantle cell lymphoma identified by SOX11 expression were similar to those of patients with conventional mantle cell lymphoma.
  • CONCLUSIONS: SOX11 mRNA and nuclear protein expression is a highly specific marker for both cyclin D1-positive and negative mantle cell lymphoma.

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 2006 Aug;56(8):440-8 [16872438.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1109-10 [16861358.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1216-22 [17296973.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):750-62 [17891190.001]
  • [Cites] Blood. 2008 Jan 15;111(2):800-5 [17934069.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1745-6 [18223179.001]
  • [Cites] Blood. 2007 Jan 1;109(1):271-80 [16960149.001]
  • [Cites] Haematologica. 2006 Jan;91(1):11-6 [16434365.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2253-61 [10733493.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2837-44 [11675358.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):185-97 [12620412.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):760-6 [14608904.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1051-6 [15252312.001]
  • [Cites] J Clin Pathol. 1989 Sep;42(9):962-72 [2794086.001]
  • [Cites] Am J Surg Pathol. 1991 Sep;15(9):819-28 [1951841.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):59-68 [9888704.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4365-74 [10361135.001]
  • [Cites] Haematologica. 2008 May;93(5):641-5 [18450732.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5683-90 [18391076.001]
  • [Cites] Histopathology. 2008 Jul;53(1):20-9 [18518902.001]
  • [Cites] Br J Haematol. 2008 Aug;142(4):538-50 [18564361.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Dec;47(12):1086-97 [18709664.001]
  • [Cites] Br J Haematol. 2008 Oct;143(2):248-52 [18729857.001]
  • [Cites] Haematologica. 2008 May;93(5):680-7 [18367489.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):516-26 [16098065.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4315-21 [16123218.001]
  • [CommentIn] Haematologica. 2009 Nov;94(11):1488-92 [19880776.001]
  • [ErratumIn] Haematologica. 2010 Sep;95(9):1620
  • (PMID = 19880778.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA114778; United States / NCI NIH HHS / CA / 5U01CA114778-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / SOX11 protein, human; 0 / SOXC Transcription Factors; 136601-57-5 / Cyclin D1
  • [Other-IDs] NLM/ PMC2770966
  •  go-up   go-down


70. Cui T, Wang C, He H, Shi G, Hu L: A rare case of ovarian Burkitt lymphoma associated tumor lysis syndrome. Eur J Gynaecol Oncol; 2010;31(2):209-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of ovarian Burkitt lymphoma associated tumor lysis syndrome.
  • A bilateral salpingo-oophorectomy was performed and pathological diagnosis showed Burkitt lymphoma of bilateral ovaries.
  • This is the first report on the post-treatment tumor lysis syndrome with ovarian Burkitt's lymphoma.
  • [MeSH-major] Burkitt Lymphoma / drug therapy. Cisplatin / adverse effects. Ovarian Neoplasms / drug therapy. Tumor Lysis Syndrome / etiology
  • [MeSH-minor] Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans. Ovariectomy. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20527243.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


71. Zeytinoğlu A, Hekimgil M, Erensoy S, Aydemir S, Berber S, Cağirgan S, Soydan S, Bilgiç A: [Investigation of Epstein-Barr virus DNA and RNA in tissues of patients with lymphoma]. Mikrobiyol Bul; 2005 Oct;39(4):473-81
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Investigation of Epstein-Barr virus DNA and RNA in tissues of patients with lymphoma].
  • Relation between Epstein-Barr virus (EBV) and nasopharyngeal carsinoma, Burkitt's lymphoma, and lymphomas in immunosupressed patients have been shown previously in different studies.
  • The same relationship was also shown in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) by some researchers.
  • The aim of this study was to demonstrate EBV nucleic acids in tissue sections of adult patients with lymphoma.
  • The presence of EBV encoded RNA (EBER) were investigated with in situ hybridization and EBV-DNA with PCR method in 29 formalin-fixed paraffin-embedded tissue sections (19 lymph nodes, the others being gastric, orbital, skin, salivary gland, testicle, small intestinal, tongue root, bone marrow and gingival tissues) of 8 patients with HL and 21 patients with NHL who were followed-up in Haematology Clinics of our university hospital.
  • [MeSH-major] DNA, Viral / isolation & purification. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / virology. Lymphoma, Non-Hodgkin / virology. RNA, Viral / isolation & purification
  • [MeSH-minor] Adolescent. Adult. Aged. Humans. In Situ Hybridization. Middle Aged. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16544549.001).
  • [ISSN] 0374-9096
  • [Journal-full-title] Mikrobiyoloji bülteni
  • [ISO-abbreviation] Mikrobiyol Bul
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / RNA, Viral
  •  go-up   go-down


72. Mendiolaza J, Baltasar JF, Anis A, Harrison J, Chen F, Klapholz M, Saric M: Left ventricular non-Hodgkin lymphoma visualized on contrast echocardiography. J Clin Ultrasound; 2007 Oct;35(8):462-4
Hazardous Substances Data Bank. Octafluoropropane .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Left ventricular non-Hodgkin lymphoma visualized on contrast echocardiography.
  • We present a case of AIDS-related Burkitt's type cardiac lymphoma in a middle-aged woman with Epstein-Barr virus infection and profound immunodeficiency.
  • [MeSH-major] Contrast Media / administration & dosage. Fluorocarbons. Heart Neoplasms / ultrasonography. Lymphoma, Non-Hodgkin / ultrasonography
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Follow-Up Studies. Heart Ventricles / ultrasonography. Humans. Injections, Intravenous. Microspheres

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley Periodicals, Inc.
  • (PMID = 17373683.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Fluorocarbons; CK0N3WH0SR / perflutren
  •  go-up   go-down


73. Attias D, Weitzman S: The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence. Curr Opin Pediatr; 2008 Feb;20(1):17-22
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence.
  • PURPOSE OF REVIEW: This review evaluates whether rituximab has efficacy in high-grade pediatric B-cell lymphoma/leukemia.
  • Current pediatric protocols for CD20+ B-cell lymphoma/leukemia significantly improve survival, but with major morbidity.
  • To assess whether rituximab has efficacy in very high-grade pediatric disease, all published data on rituximab therapy for Burkitt's lymphoma/B acute lymphoblastic leukaemia (B-ALL) and pediatric patients with relapsed/refractory large B-cell lymphoma were reviewed.
  • RECENT FINDINGS: Three trials in adult Burkitt's/B-ALL showed a significant survival advantage when rituximab was added to standard chemotherapy.
  • Minimal pediatric data have been published, but 19 children with mature B-cell lymphoma/B-ALL received rituximab, alone or in combination with chemotherapy, as salvage therapy, after failure of intensive chemotherapy.
  • SUMMARY: Rituximab has demonstrated efficacy in Burkitt's disease in adults.
  • Although positive reporting bias is suspected, it appears that rituximab, even as monotherapy, has efficacy in heavily pretreated pediatric patients with high-grade B-lymphoma/B-ALL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Child. Humans. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18197034.001).
  • [ISSN] 1040-8703
  • [Journal-full-title] Current opinion in pediatrics
  • [ISO-abbreviation] Curr. Opin. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 53
  •  go-up   go-down


74. Sant M, Allemani C, De Angelis R, Carbone A, de Sanjosè S, Gianni AM, Giraldo P, Marchesi F, Marcos-Gragera R, Martos-Jiménez C, Maynadié M, Raphael M, Berrino F, EUROCARE-3 Working Group: Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. Eur J Cancer; 2008 Mar;44(4):579-87
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States.
  • We explored the influence of morphology on geographic differences in 5-year survival for non-Hodgkin lymphoma (NHL) diagnosed in 1990-1994 and followed for 5years: 16,955 cases from 27 EUROCARE-3 cancer registries, and 22,713 cases from 9 US SEER registries.
  • Excess risk of death was significantly above reference (diffuse B lymphoma) for Burkitt's and NOS lymphoma; not different for lymphoblastic and other T-cell; significantly below reference (in the order of decreasing relative excess risk) for NHL NOS, mantle cell/centrocytic, lymphoplasmacytic, follicular, small lymphocytic/chronic lymphocytic leukaemia, other specified NHL and cutaneous morphologies.
  • [MeSH-major] Lymphoma, Non-Hodgkin / mortality. Registries / standards
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child. Child, Preschool. Europe. Feasibility Studies. Humans. Infant. Middle Aged. Prognosis. United States

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18242077.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Oberaigner W; Storm HH; Aareleid T; Hédelin G; Tron I; Le Gall E; Launoy G; Macé-Lesec'h J; Faivre J; Chaplain G; Carli PM; Danzon A; Tretarre B; Colonna M; Lacour B; Raverdy N; Berger C; Freycon F; Grosclaude P; Estêve J; Kaatsch P; Ziegler H; Hölzel D; Fritschle GS; Tryggvadottir L; Berrino F; Allemani C; Balli P; Ciccolallo L; Crosignani P; Gatta G; Micheli A; Sant M; Ferretti S; Conti E; Ramazzotti V; Vercelli M; Quaglia A; Pannelli F; Federico M; Artioloi ME; Ponze De Leon M; Benatti P; De Lisi V; Servente L; Zanetti R; Patriarca S; Magnani C; Pastore G; Gafà L; Tumino R; Falcini F; Budroni M; Paci E; Crocetti E; Zambon P; Guzzinati S; Capocaccia R; Carrani E; De Angelis R; Roazzi P; Santaquilani M; Tavilla A; Valente F; Verdecchia A; Dalmas M; Langmark F; Andersen A; Rachtan J; Bielska-Lasota M; Wronkowski Z; Plesko I; Obsitníková A; Pompe-Kirn V; Izarzugaza I; Martinez-Garcia C; Garau I; Navarro C; Chirlaque MD; Ardanaz E; Moreno C; Galceran J; Torrella A; Peris-Bonet R; Barlow L; Möller T; Jundt G; Lutz JM; Usel M; Coebergh JW; van der Does-van den Berg A; Visser O; Godward S; Forman D; Quinn MJ; Roche M; Edwards S; Stiller C; Verne J; Møller H; Bell J; Botha JL; Lawrence G; Black R; Steward JA; Conti E
  •  go-up   go-down


75. Sakane-Ishikawa E, Nakatsuka S, Tomita Y, Fujita S, Nakamichi I, Takakuwa T, Sugiyama H, Fukuhara S, Hino M, Kanamaru A, Soma T, Tsukaguchi M, Igarashi K, Kanakura Y, Aozasa K, Osaka Lymphoma Study Group: Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. J Clin Oncol; 2005 Nov 1;23(31):8012-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group.
  • PURPOSE: BACH2, a B-cell-specific transcription repressor, is abundantly expressed in lymphocytes of B-cell lineage as well as B-cell lymphoma cell lines.
  • BACH2 possesses an inhibitory effect on proliferation of Raji cell lines derived from Burkitt's lymphoma.
  • In this study, the prognostic significance of BACH2 expression was examined in diffuse large B-cell lymphoma (DLBCL).
  • [MeSH-major] Basic-Leucine Zipper Transcription Factors / genetics. Basic-Leucine Zipper Transcription Factors / metabolism. Carcinoma / metabolism. Gene Expression Regulation, Neoplastic. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258099.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BACH2 protein, human; 0 / Basic-Leucine Zipper Transcription Factors; 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


76. Kojima M, Tsukamoto N, Yokohama A, Suzuki Y, Shimizu K, Nishikawa M, Murayama K, Miyanaga T, Isoda A, Shimizu K, Itoh H, Masawa N, Yoshida K, Inagaki H: B-cell lymphoma associated with Sjögren's syndrome among Japanese patients: a clinicopathologic and immunohistochemical study of 15 cases. J Clin Exp Hematop; 2009 Nov;49(2):89-95
MedlinePlus Health Information. consumer health - Sjogren's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell lymphoma associated with Sjögren's syndrome among Japanese patients: a clinicopathologic and immunohistochemical study of 15 cases.
  • To clarify the clinicopathological findings of B-cell lymphoma associated with Sjögren's syndrome (SJS) among Japanese Patients, 15 individuals with this disease were studied.
  • Histologically, six cases were marginal zone B-cell lymphoma (MZBL) of the mucosa-associated lymphoid tissue (MALT) type, three cases were diffuse large B-cell lymphoma (DLBCL) + MALT type lymphoma, two cases were nodal MZBL and one case each was small lymphocytic lymphoma, Burkitt's lymphoma, CD10(+) DLBCL and DLBCL + nodal MZBL.
  • Using in situ hybridization, numerous Epstein-Barr virus(+) tumor cells were detected only in the case of Burkitt lymphoma.
  • B-cell lymphoma associated with SJS also frequently affected extranodal organs in patients from Japan as well as from patients in Western countries.
  • The majority of B-cell lymphomas in patients with SJS also appear to be low-grade MZBLs or high-grade lymphomas probably derived from MZBL both in Western countries and in Japan.
  • [MeSH-major] Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Salivary Gland Neoplasms / metabolism. Salivary Gland Neoplasms / pathology. Sjogren's Syndrome / metabolism. Sjogren's Syndrome / pathology
  • [MeSH-minor] Adult. Aged. Asian Continental Ancestry Group. Female. Humans. Immunohistochemistry / methods. Japan. Male. Middle Aged. Mucous Membrane / metabolism. Mucous Membrane / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19907113.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


77. Salzburg J, Burkhardt B, Zimmermann M, Wachowski O, Woessmann W, Oschlies I, Klapper W, Wacker HH, Ludwig WD, Niggli F, Mann G, Gadner H, Riehm H, Schrappe M, Reiter A: Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol; 2007 Sep 1;25(25):3915-22
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
  • PURPOSE: We analyzed the prevalence, clinical pattern, and prognostic impact of CNS involvement in a large cohort of children and adolescents diagnosed with non-Hodgkin's lymphoma (NHL), with special attention to differences according to NHL subtype.
  • The percentage of CNS-positive patients was 8.8% for Burkitt's lymphoma/Burkitt's leukemia (BL/B-ALL), 5.4% for precursor B-lymphoblastic lymphoma (pB-LBL), 3.3% for anaplastic large-cell lymphoma, 3.2% for T-cell-LBL, 2.6% for diffuse large B-cell lymphoma, and 0% for primary mediastinal large B-cell NHL (P < .001).
  • [MeSH-major] Brain Neoplasms / epidemiology. Head and Neck Neoplasms / epidemiology. Lymphoma, Non-Hodgkin / classification. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Epidural Neoplasms / epidemiology. Epidural Neoplasms / therapy. Female. Germany / epidemiology. Humans. Infant. Infant, Newborn. Male. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prevalence. Prognosis. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17761975.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


78. Duncan VE, Reddy VV, Jhala NC, Chhieng DC, Jhala DN: Non-Hodgkin's lymphoma of the breast: a review of 18 primary and secondary cases. Ann Diagn Pathol; 2006 Jun;10(3):144-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma of the breast: a review of 18 primary and secondary cases.
  • We evaluated the clinical features, morphology, and incidence of 18 cases of breast lymphoma over 10 years at the University of Alabama at Birmingham.
  • One case was diagnosed by fine needle aspiration as atypical cells, favor benign; the biopsy revealed diffuse large B-cell lymphoma.
  • Tissue diagnoses revealed that 11 cases (61%) represented diffuse large B-cell lymphoma and 3 (17%) were follicular lymphomas.
  • The remaining 4 cases (22%) were plasma cell neoplasm, T-cell neoplasm, Burkitt's lymphoma, and precursor B-cell lymphoblastic lymphoma.
  • Flow cytometry and/or gene rearrangement supported the diagnosis of lymphoma in 8 cases.
  • Although rare, lymphoma should be considered in the differential diagnosis of a breast mass.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Female. Gene Rearrangement. Humans. Immunophenotyping. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16730308.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Chennupati SK, Govindaraj S, Setzen G, Chiu AG: Adult Burkitt lymphoma originating in the sphenoid sinus: case report and review of the literature. Ear Nose Throat J; 2009 Jul;88(7):E07

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult Burkitt lymphoma originating in the sphenoid sinus: case report and review of the literature.
  • Burkitt lymphoma is a high-grade B-cell non-Hodgkin lymphoma.
  • The presence of any type of lymphoma in the paranasal sinuses is rare.
  • We report a case of Burkitt lymphoma that originated in the sphenoid sinus in a 66-year-old white woman.
  • An endoscopic sphenoidotomy was performed to obtain a tissue specimen, and a diagnosis of sporadic Burkitt lymphoma was established on the basis of its clinical, morphologic, and immunohistochemical characteristics.
  • This case is one of the few reported cases of true adult Burkitt lymphoma originating in the sphenoid sinus.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Paranasal Sinus Neoplasms / diagnosis. Sphenoid Sinus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19623516.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


80. de Larrinoa AF, del Cura J, Zabala R, Fuertes E, Bilbao F, Lopez JI: Value of ultrasound-guided core biopsy in the diagnosis of malignant lymphoma. J Clin Ultrasound; 2007 Jul-Aug;35(6):295-301
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of ultrasound-guided core biopsy in the diagnosis of malignant lymphoma.
  • Five diagnostic categories were considered: large B-cell lymphomas (LBCL), small B-cell lymphomas (SBCL), Hodgkin's disease (HD), T cell lymphomas, and miscellaneous.
  • SBCL (39), LBCL (36), HD (15), T cell lymphomas (5), and miscellaneous (7) [including T cell-rich B cell (2), natural killer cell (1), Burkitt's lymphoma (1), and non-Hodgkin's lymphoma of the B cell type, NOS (3)] were correctly diagnosed.
  • Three HDs, 1 natural killer cell lymphoma, 1 follicular lymphoma, and 1 LBCL were not correctly diagnosed.
  • [MeSH-major] Biopsy / methods. Lymphoma / diagnosis. Ultrasonography, Interventional
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Female. Hodgkin Disease / diagnosis. Humans. Killer Cells, Natural / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymph Nodes / pathology. Lymphoma, B-Cell / diagnosis. Lymphoma, Follicular / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, T-Cell / diagnosis. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Biopsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley Periodicals, Inc.
  • (PMID = 17486566.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Nomura Y, Karube K, Suzuki R, Ying G, Takeshita M, Hirose S, Nakamura S, Yoshino T, Kikuchi M, Ohshima K: High-grade mature B-cell lymphoma with Burkitt-like morphology: results of a clinicopathological study of 72 Japanese patients. Cancer Sci; 2008 Feb;99(2):246-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade mature B-cell lymphoma with Burkitt-like morphology: results of a clinicopathological study of 72 Japanese patients.
  • The aim of the present study was to estimate optimum chemotherapeutic regimens for high-grade mature B-cell lymphoma cases with Burkitt-like morphology (Burkitt's lymphoma [BL]/Burkitt-like lymphoma [BLL]) patients.
  • We analyzed 72 BL/BLL, including 36 with the c-myc translocation (molecular BL [mBL]), 20 without it (mBL-like), and 16 in whom we were uncertain regarding the existence of the c-myc translocation, and compared them with 182 diffuse large B-cell lymphoma (DLBCL) cases.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Female. Humans. Immunohistochemistry. Immunophenotyping. Japan. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18271922.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


82. Sun XF, Liu DG, Zhen ZJ, Chen XQ, Xia Y, Wang ZH, He YJ, Guan ZG: [Efficacy of short-term and intensive chemotherapy for the treatment of childhood and adolescent B cell non-Hodgkin's lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2005 Oct;26(10):581-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of short-term and intensive chemotherapy for the treatment of childhood and adolescent B cell non-Hodgkin's lymphoma].
  • OBJECTIVES: To evaluate the efficacy and toxicity of the B-NHL-BFM-90 protocol in the treatment of Chinese childhood and adolescent B-cell non-Hodgkin's lymphomas (B-NHL).
  • Of them 18 cases were Burkitt's lymphoma, 16 diffuse large B cell lymphoma and 8 anaplastic lymphoma.
  • Of the 5 PR patients, I received autologous hematopoietic stem cell transplantation, 3 received radiotherapy for residual disease and 1 just under watching.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Feasibility Studies. Female. Follow-Up Studies. Humans. Infant. Male. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16532964.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


83. Panayotakopoulos GD, Day S, Peters BS, Kulasegaram R: Severe osteoporosis and multiple fractures in an AIDS patient treated with short-term steroids for lymphoma: a need for guidelines. Int J STD AIDS; 2006 Aug;17(8):567-8
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe osteoporosis and multiple fractures in an AIDS patient treated with short-term steroids for lymphoma: a need for guidelines.
  • An HIV-1 infected patient on dual protease inhibitor treatment developed spontaneous vertebral fractures and avascular necrosis of the femoral bone after receiving combined chemotherapy for Burkitt's lymphoma including short-term prednisolone.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / virology. Fractures, Compression / etiology. HIV-1. Osteoporosis / etiology. Prednisolone / adverse effects
  • [MeSH-minor] Adult. Anti-Retroviral Agents / therapeutic use. HIV Protease Inhibitors / therapeutic use. Humans. Male


84. Hassan A, Kreisel F, Gardner L, Lewis JS Jr, El-Mofty SK: Plasmablastic lymphoma of head and neck: report of two new cases and correlation with c-myc and IgVH gene mutation status. Head Neck Pathol; 2007 Dec;1(2):150-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma of head and neck: report of two new cases and correlation with c-myc and IgVH gene mutation status.
  • Plasmablastic lymphoma (PBL) is a rare acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma (AIDS-NHL), with predilection for the mucosa of oral cavity.
  • It usually has a plasmablastic morphology, expressing plasma cell-associated antigens with weak or absent expression of B-cell-associated markers.
  • Although current literature suggests that most cases of c-myc gene rearranged AIDS-NHL are Burkitt's lymphoma, our case has an immunophenotype characteristic for PBL.
  • The concurrent B-cell immunophenotype of BCL-6(-)/CD138(+)/MUM-1(+) also suggests a post-germinal center B-cell origin of this lymphoma.
  • The immunophenotype of our second case (BCL-6(-)/CD138(+)/MUM-1(+)) also suggests a post-germinal center B-cell origin.
  • [MeSH-major] Immunoglobulin Heavy Chains / genetics. Immunoglobulin Variable Region / genetics. Lymphoma, AIDS-Related / pathology. Lymphoma, Large-Cell, Immunoblastic / pathology. Mouth Neoplasms / pathology. Proto-Oncogene Proteins c-myc / genetics
  • [MeSH-minor] Adult. Gene Rearrangement, B-Lymphocyte. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation. Somatic Hypermutation, Immunoglobulin / genetics. Somatic Hypermutation, Immunoglobulin / immunology

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):77-81 [15621784.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):806-15 [15578069.001]
  • [Cites] Cancer. 2005 Jun 25;105(3):139-44 [15803491.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Aug;100(2):198-206 [16037778.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]
  • [Cites] Ann Diagn Pathol. 2006 Feb;10(1):8-12 [16414538.001]
  • [Cites] Oral Oncol. 2002 Jan;38(1):96-102 [11755827.001]
  • [Cites] Hum Pathol. 2002 Apr;33(4):392-404 [12055673.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):622-8 [12437635.001]
  • [Cites] Histopathology. 2003 Jun;42(6):605-9 [12786898.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3928-32 [14581416.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):95-100 [9709310.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Blood. 1993 Jan 1;81(1):166-76 [8380252.001]
  • [Cites] Blood. 1993 Jul 15;82(2):552-63 [8392399.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Semin Diagn Pathol. 1997 Feb;14(1):67-82 [9044511.001]
  • (PMID = 20614267.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc
  • [Other-IDs] NLM/ PMC2807524
  • [Keywords] NOTNLM ; Acquired immunodeficiency syndrome-associated non-Hodgkin’s lymphoma / Immunoglobulin variable heavy chain hypermutation status / Plasmablastic lymphoma / c-myc gene rearrangement
  •  go-up   go-down


85. Hishima T, Oyaizu N, Fujii T, Tachikawa N, Ajisawa A, Negishi M, Nakamura T, Iwamoto A, Hayashi Y, Matsubara D, Sasao Y, Kimura S, Kikuchi Y, Teruya K, Yasuoka A, Oka S, Saito K, Mori S, Funata N, Sata T, Katano H: Decrease in Epstein-Barr virus-positive AIDS-related lymphoma in the era of highly active antiretroviral therapy. Microbes Infect; 2006 Apr;8(5):1301-7
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decrease in Epstein-Barr virus-positive AIDS-related lymphoma in the era of highly active antiretroviral therapy.
  • Recent introduction of highly active antiretroviral therapy (HAART) is reported to have reduced the incidence of lymphoma among HIV-infected individuals.
  • A clinicopathological study was performed on 86 AIDS-related lymphoma patients who were treated in Tokyo area from 1987 to 2005.
  • The incidence of lymphoma detected by autopsy was 27% (53 cases/198 autopsies).
  • Diffuse large B cell lymphoma was the most predominant histological subtype throughout the period (78%).
  • Burkitt's lymphoma (BL) increased from 2% in the pre-HAART era (before end-1997) to 13% in the HAART era, whereas incidence of BL did not vary between HAART users and non-users.
  • Epstein-Barr virus (EBV)-positive lymphoma decreased from 88% in the pre-HAART era to 58% in the HAART era, but did not differ significantly between HAART users (73%) and non-users (74%).
  • Nodal involvement of lymphoma increased from 14% in the pre-HAART era to 50% in the HAART era; however, central nervous system involvement decreased from 62 to 38%.
  • These data suggest that HAART might play a partial role in these changes, and the alteration in immunological backgrounds, such as EBV prevalence, is suggested as another leading cause of these changes in Japanese AIDS-related lymphoma.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16697236.001).
  • [ISSN] 1286-4579
  • [Journal-full-title] Microbes and infection
  • [ISO-abbreviation] Microbes Infect.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


86. Cheadle EJ, Gilham DE, Thistlethwaite FC, Radford JA, Hawkins RE: Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells. Br J Haematol; 2005 May;129(3):322-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells.
  • However, tumours can avoid T cell-mediated attack through multiple mechanisms including downregulation of major histocompatability complex (MHC).
  • Consequently, engineering T cells to target intact protein antigen directly, thus bypassing the need for MHC presentation, can facilitate T cell targeting of tumour cells.
  • Peripheral blood lymphocytes from nine of nine patients with non-Hodgkin lymphoma (NHL) were successfully gene-modified to express a receptor consisting of a CD19 single chain variable fragment (scFv) fused to the T cell CD3zeta signalling molecule.
  • These T cells were functionally active against the CD19(+) Raji Burkitt's lymphoma cell line.
  • [MeSH-major] Antigens, CD19 / analysis. Lymphocyte Transfusion / methods. Lymphoma, Non-Hodgkin / pathology. T-Lymphocyte Subsets / immunology
  • [MeSH-minor] Adult. Aged. Antigens, CD3 / immunology. Biopsy. Cytotoxicity, Immunologic. Female. Genetic Vectors. Humans. Immunotherapy, Adoptive / methods. Interferon-gamma / biosynthesis. Lymphocyte Activation. Male. Middle Aged. Retroviridae / genetics. Transduction, Genetic. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842655.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD3; 0 / CD3 antigen, zeta chain; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


87. Haddadin WJ: Malignant lymphoma in Jordan: a retrospective analysis of 347 cases according to the World Health Organization classification. Ann Saudi Med; 2005 Sep-Oct;25(5):398-403
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma in Jordan: a retrospective analysis of 347 cases according to the World Health Organization classification.
  • BACKGROUND: Most studies describing the subtypes of lymphoma in Jordan were carried out in the 1980s at a time when immunohistochemical facilities were unavailable.
  • Using a database established after immunohistochemical studies were introduced, we determined the frequency of the various types of nodal and extranodal lymphomas in the adult and paediatric Jordanian population.
  • We also assessed the incidence of bone marrow involvement at the initial presentation for each lymphoma type.
  • METHODS: A retrospective analysis of the histopathological subtypes of various lymphomas was conducted on all primary lymphoma cases diagnosed during a 3-year period between January 2001 and December 2003.
  • RESULTS: Of 347 patients included in the study, 78.4% had non-Hodgkin's lymphoma (NHL) and 21.6% had Hodgkin's lymphoma (HL).
  • In the NHL group, diffuse large B-cell lymphoma was the most common (28.2%) followed by follicular lymphoma (15.6%).
  • Of all the lymphoma cases, the highest incidence of marrow involvement was seen in patients with lymphoplasmacytic lymphoma.
  • Forty-nine patients were children (age <15 years) in whom Burkitt's lymphoma (15 cases) and HL (14 cases) were the commonest subtypes.
  • Among the various lymphomas, diffuse large B-cell lymphoma is the most commonly encountered lymphoma in adults.
  • Burkitt's lymphoma and Hodgkin's disease are the most frequent childhood lymphomas, followed closely by lymphoblastic lymphoma.
  • [MeSH-major] Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Incidence. Jordan / epidemiology. Male. Middle Aged. Retrospective Studies. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270763.001).
  • [ISSN] 0256-4947
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


88. Chao C, Xu L, Abrams D, Leyden W, Horberg M, Towner W, Klein D, Tang B, Silverberg M: Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS; 2010 Jul 17;24(11):1765-70
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy.
  • OBJECTIVE: To investigate the survival outcomes for non-Hodgkin lymphoma (NHL) in HIV-infected vs. uninfected patients from the same integrated healthcare system, and to identify prognostic factors for HIV-related NHL in the era of combined antiretroviral therapy.
  • Two-year all-cause and lymphoma-specific mortality by HIV status were examined using multivariable Poisson regression.
  • Among HIV-infected patients, prognostic factors of demographics, lymphoma, and HIV-related characteristics for the same outcomes were also examined.
  • This elevated mortality risk for HIV-infected patients was similar for all race groups, lymphoma stages, and histologic subtypes.
  • HIV-infected patients with CD4 cell count below 200 cells/microl, prior AIDS-defining illness, or both were also at increased risk for lymphoma-specific mortality as compared with HIV-uninfected patients.
  • Among HIV-infected NHL patients, significant prognostic factors for overall mortality included prior AIDS-defining illness and Burkitt's subtype.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Oct 15;96(8):2730-4 [11023505.001]
  • [Cites] AIDS Read. 2004 Nov;14(11):605-17 [15570672.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2171-8 [11304769.001]
  • [Cites] Leuk Lymphoma. 2001 Mar;41(1-2):105-16 [11342362.001]
  • [Cites] AIDS Res Hum Retroviruses. 2002 Mar 1;18(4):237-42 [11860669.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 Aug 15;30(5):478-84 [12154338.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] Clin Infect Dis. 2003 Dec 1;37(11):1556-64 [14614680.001]
  • [Cites] Clin Infect Dis. 2004 Jan 1;38(1):142-4 [14679461.001]
  • [Cites] Am J Epidemiol. 2004 Aug 15;160(4):301-5 [15286014.001]
  • [Cites] HIV Med. 2004 Sep;5(5):377-84 [15369514.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2943-6 [15238428.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):613-9 [1607900.001]
  • [Cites] Ann Intern Med. 2005 Aug 16;143(4):265-73 [16103470.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8477-82 [16230675.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):167-73 [17117144.001]
  • [Cites] Antivir Ther. 2007;12(6):931-9 [17926647.001]
  • [Cites] Lancet. 2009 Apr 18;373(9672):1352-63 [19361855.001]
  • [Cites] AIDS. 2009 Nov 13;23(17):2337-45 [19741479.001]
  • [Cites] Cancer. 2001 Jan 1;91(1):155-63 [11148572.001]
  • (PMID = 20453630.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA134234-01; United States / NIAID NIH HHS / AI / AI071725-01A1; United States / NIAID NIH HHS / AI / K01 AI071725; United States / NCI NIH HHS / CA / R01 CA134234-01; United States / NIAID NIH HHS / AI / K01 AI071725-01A1; United States / NCI NIH HHS / CA / R01CA134234; United States / NIAID NIH HHS / AI / K01AI071725; United States / NCI NIH HHS / CA / R01 CA134234
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Other-IDs] NLM/ NIHMS198983; NLM/ PMC2895006
  •  go-up   go-down


89. Morton LM, Zheng T, Holford TR, Holly EA, Chiu BC, Costantini AS, Stagnaro E, Willett EV, Dal Maso L, Serraino D, Chang ET, Cozen W, Davis S, Severson RK, Bernstein L, Mayne ST, Dee FR, Cerhan JR, Hartge P, InterLymph Consortium: Alcohol consumption and risk of non-Hodgkin lymphoma: a pooled analysis. Lancet Oncol; 2005 Jul;6(7):469-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alcohol consumption and risk of non-Hodgkin lymphoma: a pooled analysis.
  • BACKGROUND: Previous epidemiological studies of the relation between alcohol consumption and risk of non-Hodgkin lymphoma (NHL) have been inconsistent, probably because of small sample sizes of individual studies that result from stratification by NHL subtype and type of alcoholic beverage.
  • METHODS: We obtained original data from nine case-control studies from the USA, UK, Sweden, and Italy in the International Lymphoma Epidemiology Consortium (InterLymph), yielding a pooled study population of 15 175 individuals (6492 cases and 8683 controls).
  • FINDINGS: People who drank alcohol had a lower risk of NHL than did non-drinkers (OR 0.83 [95% CI 0.76-0.89]).
  • Compared with non-drinkers, risk estimates were lower for current drinkers than for former drinkers (0.73 [0.64-0.84] vs 0.95 [0.80-1.14]), but risk did not decrease with increasing alcohol consumption.
  • The lowest risk estimates were recorded for Burkitt's lymphoma (0.51 [0.33-0.77]).
  • [MeSH-major] Alcohol Drinking. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged. Odds Ratio. Risk Factors

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Alcohol.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2005 Jul;6(7):443-4 [15992691.001]
  • (PMID = 15992695.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 10349; United States / NCI NIH HHS / CA / CA 45614; United States / NCI NIH HHS / CA / CA 50850; United States / NCI NIH HHS / CA / CA 51086; United States / NCI NIH HHS / CA / CA 62006; United States / NCI NIH HHS / CA / CA 69269; United States / NCI NIH HHS / CA / CA 89745; United States / NCI NIH HHS / PC / PC 65064; United States / NCI NIH HHS / PC / PC 67008; United States / NCI NIH HHS / PC / PC 67009; United States / NCI NIH HHS / PC / PC 67010; United States / NCI NIH HHS / PC / PC 71105
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


90. Suzuki K, Nakazato T, Sanada Y, Mihara A, Tachikawa N, Kurai H, Yoshimura Y, Hayashi H, Yoshida S, Kakimoto T: [Successful treatment with hyper-CVAD and highly active anti-retroviral therapy (HAART) for AIDS-related Burkitt lymphoma]. Rinsho Ketsueki; 2010 Mar;51(3):207-12
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment with hyper-CVAD and highly active anti-retroviral therapy (HAART) for AIDS-related Burkitt lymphoma].
  • Colonoscopy was performed and histological examination of the colon tumor revealed Burkitt's lymphoma (BL).
  • In the HAART era, the survival of patients with AIDS-related diffuse large cell lymphoma (DLCL) improved dramatically, whereas the survival of similarly treated patients with AIDS-related BL remained poor.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Burkitt Lymphoma / drug therapy. Colonic Neoplasms / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Prednisone / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20379116.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CVAD protocol; EPOCH protocol
  •  go-up   go-down


91. Huang WT, Chuang SS, Eng HL, Huanga CC: Synchronous CIN 3 and cervical lymphoma: a case report and review of the literature. Pathol Res Pract; 2005;201(7):521-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous CIN 3 and cervical lymphoma: a case report and review of the literature.
  • Primary cervical lymphoma is rare, with less than 60 cases reported in the English literature, including a few cases of synchronous cervical intraepithelial neoplasia (CIN) with cervical lymphoma.
  • We describe a 42-year-old woman with CIN 3 and malignant lymphoma of the cervix.
  • The histology of the cervix revealed diffuse infiltration of monotonous medium-sized lymphoid cells with dispersing tingible bodies, and a Burkitt's lymphoma in combination with a small CIN 3 lesion was diagnosed.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / pathology. Lymphoma / pathology. Neoplasms, Multiple Primary / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Genes, Immunoglobulin. Herpesvirus 4, Human. Humans. In Situ Hybridization. Neoplasm Staging. Papanicolaou Test. Papillomaviridae. Polymerase Chain Reaction. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16164048.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


92. Zerwas E, Kemper-Martin A, Comes A: A case report of adult colonic intussusception. J La State Med Soc; 2008 Mar-Apr;160(2):102-3, 105
MedlinePlus Health Information. consumer health - Colonic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case report of adult colonic intussusception.
  • Pathology demonstrated a transverse colo-colonic intussusception with an intraluminal focus of Burkitt's lymphoma as the lead point.
  • [MeSH-minor] Burkitt Lymphoma / complications. Burkitt Lymphoma / diagnosis. Colectomy / methods. Diagnosis, Differential. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18681354.001).
  • [ISSN] 0024-6921
  • [Journal-full-title] The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society
  • [ISO-abbreviation] J La State Med Soc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Timuragaoglu A, Dizlek S, Uysalgil N, Tosun O, Yamac K: Methylenetetrahydrofolate reductase C677T polymorphism in adult patients with lymphoproliferative disorders and its effect on chemotherapy. Ann Hematol; 2006 Dec;85(12):863-8
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylenetetrahydrofolate reductase C677T polymorphism in adult patients with lymphoproliferative disorders and its effect on chemotherapy.
  • Although it was not statistically significant, we found a 2.7-fold increased risk in acute lymphocytic leukaemia (ALL)/Burkitt lymphoma patients with TT genotype [odds ratio (OR), 2.7; 95% confidence interval (CI), 0.88-8.2] than CC genotype but a 1.7-fold decreased risk with TT genotype in diffuse large B-cell lymphoma (DLBCL; OR, 0.58; 95% CI, 0.17-1.88) and a 1.8-fold decreased risk in Hodgkin's lymphoma with TT genotype (OR, 0.55; 95% CI, 0.10-2.87) than CC genotype.
  • The chemotherapy response was analysed in DLBCL, Hodgkin's lymphoma and ALL/Burkitt's lymphoma because these patients received standard chemotherapy protocols.
  • No significant difference was detected between responder and non-responders according to MTHFR T677C polymorphism, but the patients who had TT genotype respond 1.75-fold worse than CC (OR, 0.57; 95% CI, 0.07-4.64) in ALL patients (p=0.59), and in DLBCL, CT genotype revealed a 1.8-fold worse response than CC genotype (OR, 0.54; 95% CI, 0.17-1.7), but TT genotype revealed 2.6-fold better response rates than patients with CC genotype (OR, 2.6; 95% CI, 0.26-26.8).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / genetics. Female. Genetic Predisposition to Disease. Genotype. Hodgkin Disease / drug therapy. Hodgkin Disease / genetics. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / genetics. Male. Middle Aged. Risk. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Hematol. 2007 May;86(5):389 [17211521.001]
  • (PMID = 16944145.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


94. Aldoss IT, Weisenburger DD, Fu K, Chan WC, Vose JM, Bierman PJ, Bociek RG, Armitage JO: Adult Burkitt lymphoma: advances in diagnosis and treatment. Oncology (Williston Park); 2008 Nov 30;22(13):1508-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult Burkitt lymphoma: advances in diagnosis and treatment.
  • Burkitt lymphoma is a unique B-cell malignancy with a high proliferation rate and characteristic genetic changes involving the c-myc oncogene.
  • Burkitt lymphoma is common in children but also occurs in adults, where distinction from diffuse large B-cell lymphoma may pose a problem.
  • The development of brief, very intensive chemotherapy regimens has led to a very high cure rate in children with Burkitt lymphoma.
  • Burkitt lymphoma in adults cannot be treated effectively with the common regimens used for diffuse large B-cell lymphoma such as CHOP-R (cyclophosphamide, doxorubicin HCl, vincristine [Oncovin], prednisone, rituximab).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Clinical Trials, Phase II as Topic. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Genes, myc. Humans. Ifosfamide / administration & dosage. Leucovorin / administration & dosage. Methotrexate / administration & dosage. Practice Guidelines as Topic. Prednisone / administration & dosage. Prognosis. Rituximab. Stem Cell Transplantation / methods. Survival Analysis. Teniposide / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Oncology (Williston Park). 2008 Nov 30;22(13):1518-9 [19227573.001]
  • [CommentOn] Oncology (Williston Park). 2008 Nov 30;22(13):1519, 1522-3 [19227574.001]
  • (PMID = 19133605.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Comment; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 957E6438QA / Teniposide; Q573I9DVLP / Leucovorin; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 89
  •  go-up   go-down


95. Song KW, Barnett MJ, Gascoyne RD, Horsman DE, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Voss NJ, Toze CL, Connors JM: Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma. Br J Haematol; 2006 Jun;133(6):634-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma.
  • High dose chemoradiotherapy and haematopoietic stem cell transplantation (SCT) is used as primary therapy for patients diagnosed with Burkitt lymphoma (BL).
  • [MeSH-major] Burkitt Lymphoma / therapy. Hematopoietic Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16704438.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


96. Adeyemi BF, Kolude BM, Ogun GO, Akang EE: Paediatric head and neck malignancies in Ibadan, Nigeria. Afr J Med Med Sci; 2009 Mar;38(1):55-62
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most studies have been restricted to specific histological types such as rhabdomyosarcoma, osteogenic sarcoma or Burkitt's lymphoma.
  • Burkitt's lymphoma constituted 28.6%, followed by rhabdomyosarcoma accounting for 17.9% of cases.
  • The pattern of these neoplasms also differs from that in the adult population.
  • However, malignant head and neck neoplasms in the paediatric age group also showed the male preponderance characteristic of head and neck malignancies in the adult population.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Lymphoma / epidemiology. Male. Neoplasms, Germ Cell and Embryonal / epidemiology. Neoplasms, Glandular and Epithelial / epidemiology. Nigeria / epidemiology. Retrospective Studies. Risk Factors. Sarcoma / epidemiology. Sex Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19722429.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


97. Oriol A, Ribera JM, Bergua J, Giménez Mesa E, Grande C, Esteve J, Brunet S, Moreno MJ, Escoda L, Hernandez-Rivas JM, Hoelzer D: High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer; 2008 Jul 1;113(1):117-25
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients.
  • BACKGROUND: It has been recognized that cure is possible for human immunodeficiency virus (HIV)-infected patients with Burkitt lymphoma/leukemia (BL) if appropriate chemotherapy is used.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal, Murine-Derived. Drug Administration Schedule. Feasibility Studies. Female. Humans. Immunotherapy. Male. Middle Aged. Remission Induction. Rituximab. Survival Analysis

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Copyright) 2008 American Cancer Society.
  • (PMID = 18457327.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


98. Carbone A, Gloghini A, Dotti G: EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist; 2008 May;13(5):577-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since its discovery as the first human tumor virus, Epstein-Barr virus (EBV) has been implicated in the development of a wide range of B-cell lymphoproliferative disorders, including Burkitt's lymphoma, classic Hodgkin's lymphoma, and lymphomas arising in immunocompromised individuals (post-transplant and HIV-associated lymphoproliferative disorders).
  • T-cell lymphoproliferative disorders that have been reported to be EBV associated include a subset of peripheral T-cell lymphomas, angioimmunoblastic T-cell lymphoma, extranodal nasal type natural killer/T-cell lymphoma, and other rare histotypes.
  • Recent advances in EBV cell-based immunotherapy, which is beginning to show promise in the treatment of EBV-related disorders, are discussed.
  • [MeSH-major] Epstein-Barr Virus Infections / classification. Herpesvirus 4, Human / genetics. Lymphoma, B-Cell / virology. Lymphoma, T-Cell / virology
  • [MeSH-minor] Adult. Disease Susceptibility. Humans. Immunocompromised Host / immunology. Immunotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18515742.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 75
  •  go-up   go-down


99. Friedrichs B, Tiemann M, Salwender H, Verpoort K, Wenger MK, Schmitz N: The effects of rituximab treatment during pregnancy on a neonate. Haematologica; 2006 Oct;91(10):1426-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 35-year old woman developed Burkitt's lymphoma and was treated with rituximab and CHOP therapy early during pregnancy.
  • Monitoring of rituximab concentrations and B-cell counts in the child revealed a transient complete B-cell depletion associated with high rituximab cord blood concentrations.
  • B-cell recovery was fast, showing a regular immunophenotype without loss of CD20 antigen, no functional deficits and adequate vaccination IgG titers.
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Burkitt Lymphoma / blood. Burkitt Lymphoma / drug therapy. Child, Preschool. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Fetal Blood / drug effects. Humans. Prednisone / administration & dosage. Pregnancy. Rituximab. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Pregnancy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16963391.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


100. Marcus KJ, Tishler RB: Head and neck carcinomas across the age spectrum: epidemiology, therapy, and late effects. Semin Radiat Oncol; 2010 Jan;20(1):52-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, in adult patients, squamous cell carcinomas or one of its variants are the most common malignancies in the head and neck.
  • However, in children, cancers of the head/neck are most commonly rhabdomyosarcomas, lymphomas, including Hodgkin's lymphoma, lymphoblastic lymphomas, and Burkitt's lymphoma or neuroblastoma.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / therapy. Lymphoma / epidemiology. Neuroblastoma / epidemiology. Rhabdomyosarcoma / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Child. Combined Modality Therapy / methods. Humans. Nasopharyngeal Neoplasms / epidemiology. Nasopharyngeal Neoplasms / pathology. Nasopharyngeal Neoplasms / therapy. Neoplasm Staging. Radiotherapy / adverse effects

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19959031.001).
  • [ISSN] 1532-9461
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down






Advertisement